CN106699810A - Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity - Google Patents
Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity Download PDFInfo
- Publication number
- CN106699810A CN106699810A CN201611021938.7A CN201611021938A CN106699810A CN 106699810 A CN106699810 A CN 106699810A CN 201611021938 A CN201611021938 A CN 201611021938A CN 106699810 A CN106699810 A CN 106699810A
- Authority
- CN
- China
- Prior art keywords
- formula
- unsubstituted
- compound shown
- substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 129
- 230000000694 effects Effects 0.000 title claims abstract description 24
- 108091000080 Phosphotransferase Proteins 0.000 title claims abstract description 14
- 102000020233 phosphotransferase Human genes 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 13
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title abstract description 8
- 230000005764 inhibitory process Effects 0.000 title abstract description 6
- 125000003118 aryl group Chemical group 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 15
- 150000002367 halogens Chemical class 0.000 claims abstract description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 11
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 8
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims abstract description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 6
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims abstract description 4
- 150000002431 hydrogen Chemical class 0.000 claims abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 2
- -1 alkane Epoxide Chemical class 0.000 claims description 82
- 239000002585 base Substances 0.000 claims description 55
- 150000003839 salts Chemical class 0.000 claims description 47
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 38
- 229940002612 prodrug Drugs 0.000 claims description 36
- 239000000651 prodrug Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 33
- 239000012453 solvate Substances 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 229910052763 palladium Inorganic materials 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 150000007530 organic bases Chemical class 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 150000007529 inorganic bases Chemical class 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 229910052723 transition metal Inorganic materials 0.000 claims description 6
- 150000003624 transition metals Chemical class 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical class ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- RQBJDYBQTYEVEG-UHFFFAOYSA-N benzylphosphane Chemical group PCC1=CC=CC=C1 RQBJDYBQTYEVEG-UHFFFAOYSA-N 0.000 claims description 4
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 125000003963 dichloro group Chemical group Cl* 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical class CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 claims description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000006414 CCl Chemical group ClC* 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical class CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- GCUVBACNBHGZRS-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-yl(diphenyl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 GCUVBACNBHGZRS-UHFFFAOYSA-N 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 claims description 2
- 229940113088 dimethylacetamide Drugs 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 claims description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 235000011056 potassium acetate Nutrition 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 239000011698 potassium fluoride Substances 0.000 claims description 2
- 235000003270 potassium fluoride Nutrition 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 238000013507 mapping Methods 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- 230000007246 mechanism Effects 0.000 abstract description 2
- 102000001301 EGF receptor Human genes 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 2
- 125000002355 alkine group Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 62
- 238000005160 1H NMR spectroscopy Methods 0.000 description 41
- 238000012795 verification Methods 0.000 description 41
- 235000002639 sodium chloride Nutrition 0.000 description 34
- 239000007787 solid Substances 0.000 description 25
- 239000002994 raw material Substances 0.000 description 22
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 238000010189 synthetic method Methods 0.000 description 17
- 150000001721 carbon Chemical group 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000006641 stabilisation Effects 0.000 description 7
- 238000011105 stabilization Methods 0.000 description 7
- 239000005864 Sulphur Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 0 C*CCC(C(C)*C)C(*C1*C(*)CC1)*=C Chemical compound C*CCC(C(C)*C)C(*C1*C(*)CC1)*=C 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 4
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102200048955 rs121434569 Human genes 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000007614 solvation Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HSDUOEHXQIUKBR-UHFFFAOYSA-N 2-N,4-N-dimethylpiperidine-2,4-diamine Chemical class CNC1NCCC(C1)NC HSDUOEHXQIUKBR-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- YFJAIURZMRJPDB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine Chemical class CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical group CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000005938 2,3-dihydro-1H-isoindolyl group Chemical group 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical group ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical group ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical class C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- HTSVYUUXJSMGQC-UHFFFAOYSA-N 2-chloro-1,3,5-triazine Chemical class ClC1=NC=NC=N1 HTSVYUUXJSMGQC-UHFFFAOYSA-N 0.000 description 1
- TYCYTQLXAIDJNF-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)pyrimidine Chemical class FC(F)(F)C1=CN=C(Cl)N=C1 TYCYTQLXAIDJNF-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical class ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- WHVCWJLWOXTCSW-UHFFFAOYSA-N CN(C)C(CC1)CCN1C(CC=C1Nc(nc2)nc(Nc(cccc3)c3P(C)(C)=O)c2Cl)C2=C1OCC2 Chemical compound CN(C)C(CC1)CCN1C(CC=C1Nc(nc2)nc(Nc(cccc3)c3P(C)(C)=O)c2Cl)C2=C1OCC2 WHVCWJLWOXTCSW-UHFFFAOYSA-N 0.000 description 1
- UPNFXJKDUKMQTC-UHFFFAOYSA-N CN(C)C(CC1)CCN1c(cc1)c(CCO2)c2c1Nc1cc(Nc(cccc2)c2P(C)(C)=O)ncn1 Chemical compound CN(C)C(CC1)CCN1c(cc1)c(CCO2)c2c1Nc1cc(Nc(cccc2)c2P(C)(C)=O)ncn1 UPNFXJKDUKMQTC-UHFFFAOYSA-N 0.000 description 1
- HEADRQZGHIGZBE-UHFFFAOYSA-N CN(C)C(CC1)CCN1c(cc1)c(CCO2)c2c1Nc1nc(Nc(cccc2)c2P(C)(C)=O)ncn1 Chemical compound CN(C)C(CC1)CCN1c(cc1)c(CCO2)c2c1Nc1nc(Nc(cccc2)c2P(C)(C)=O)ncn1 HEADRQZGHIGZBE-UHFFFAOYSA-N 0.000 description 1
- MBIHCXJDDMGEQY-UHFFFAOYSA-N CN(CC1)CCN1c(cc1)c(CCO2)c2c1Nc(nc1)nc(Nc(cccc2)c2P(C)(C)=O)c1Cl Chemical compound CN(CC1)CCN1c(cc1)c(CCO2)c2c1Nc(nc1)nc(Nc(cccc2)c2P(C)(C)=O)c1Cl MBIHCXJDDMGEQY-UHFFFAOYSA-N 0.000 description 1
- JCJAJBBXBCQDOS-HKOYGPOVSA-N CP(C)(c(cccc1)c1N/C(/N=C(\N)/Nc(cc1)c2OCCc2c1N1CCNCC1)=C(/C=C)\Cl)=O Chemical compound CP(C)(c(cccc1)c1N/C(/N=C(\N)/Nc(cc1)c2OCCc2c1N1CCNCC1)=C(/C=C)\Cl)=O JCJAJBBXBCQDOS-HKOYGPOVSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical group C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- QWBAOXACRYJBED-UHFFFAOYSA-N [Cl].C1=CN=CN=C1 Chemical compound [Cl].C1=CN=CN=C1 QWBAOXACRYJBED-UHFFFAOYSA-N 0.000 description 1
- MTHCMTVTNGNMEX-UHFFFAOYSA-N [O-][N+](c1ccc(C2CCNCC2)c2c1OCC2)=O Chemical compound [O-][N+](c1ccc(C2CCNCC2)c2c1OCC2)=O MTHCMTVTNGNMEX-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 150000001278 adipic acid derivatives Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000002634 anti-blastic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- YKYMGFHOJJOSEB-UHFFFAOYSA-N butan-1-ol;potassium Chemical compound [K].CCCCO YKYMGFHOJJOSEB-UHFFFAOYSA-N 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- MBVAHHOKMIRXLP-UHFFFAOYSA-N imidazo[1,2-a]pyrazine Chemical compound C1=CN=CC2=NC=CN21 MBVAHHOKMIRXLP-UHFFFAOYSA-N 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950005216 napadisilate Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical class C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 description 1
- 150000004893 oxazines Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 125000004309 pyranyl group Chemical class O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical compound C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical class [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940075466 undecylenate Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a nitrogen-containing heterogeneous ring compound, a preparation method thereof and an application of the nitrogen-containing heterogeneous ring compound in inhibition of kinase activity. The general formula of the nitrogen-containing heterogeneous ring compound is represented as a formula I or a formula I', wherein R1, R2, R3 and R4 in the formula I or the formula I' are selected from any one of hydrogen, halogen, cyanogroup, hydroxyl, amidogen and substituted or unsubstituted C1-C6 alkyl groups independently, and a 3-10-membered ring system can be formed by any two groups in R1, R2, R3 and R4; M1, M2 and M3 are selected from CRa or N independently, and at least one of M1, M2 and M3 is N; W is selected from substituted or unsubstituted C1-C6 alkyl groups, substituted or unsubstituted C2-C6 alkenyl, unsubstituted or halogenated 4-8-membered alkine groups, substituted or unsubstituted C3-C8 naphthenic base, substituted or unsubstituted 4-8-membered heterocyclic groups, 5-10-membered aromatic or heteroaryl groups, substituted carbonyl, substituted sulfonyl and substituted or unsubstituted amidogen. The nitrogen-containing heterogeneous ring compound can inhibit EGFR (epidermal growth factor receptor) mutant kinase activity or ALK (anaplastic lymphoma kinase) activity and is a multi-target tumor therapeutic drug with a brand-new action mechanism.
Description
Technical field
The present invention relates to a kind of nitrogen-containing heterocycle compound and preparation method thereof and the application in kinase activity is suppressed, belong to
Field of pharmaceutical chemistry technology.
Background technology
Tumor cells targeted therapy is based on the key protein closely related to tumorigenesis, by chemical means
Selectively acting is in signal protein, a kind for the treatment of method of killing tumor cell.The characteristics of targeted therapy is:It is specific high, choosing
Selecting property is strong, and toxic and side effect is low relative to classic chemotherapy medicine;During drug combination, the curative effect of classic chemotherapy can be strengthened;Targeted inhibition
Resistance is easily produced on agent clinical drug and medicine is failed.
Lung cancer is the whole world incidence of disease and case fatality rate highest malignant tumour, and survival rate is only 16.8% within 5 years, lung in 2010
The incidence of disease and case fatality rate of cancer are occupied first of all malignant tumours of China.Non-small cell lung cancer (NSCLC) accounts for all lung cancer pathology
In type 85%, the non-small cell lung cancer cause of disease is complicated, polygenes, Mutiple Targets regulation and control and easy mutation generation resistance.Non-small cell
Remedies for lung cancer thing mainly has classic chemotherapy medicine platinum class, taxanes, antibody class, neovascularization inhibitor and targeted inhibition agent
Deng, but with clinically still there is the substantial amounts of resistance patient appearance for being mutated and causing, consequently found that non-with searching overriding resistance
Therapy for small cell lung cancer medicine is still a popular domain of current industrial quarters.
In recent years, U.S. FAD have approved multiple ALK inhibitor in succession, and such as gram azoles replaces Buddhist nun, Ceritinib, and at present
The third generation EGFR inhibitor in clinical late stage, such as AZD9219, CO1686 etc. are in, but this kind of medicine is still at present
There is unsatisfactory curative effect, or selectivity it is not high the problems such as, therefore there is mutant drug-resistant higher in the urgent need to finding and finding a class
Selectivity, or the new types of therapeutic agents with multiple target spot inhibitory activity.
The content of the invention
It is an object of the invention to provide a kind of nitrogen-containing heterocycle compound and preparation method thereof with suppress kinase activity in
Using the nitrogenous hybrid compounds can be many of the brand-new mechanism of action of a class as the antiblastic of kinds of tumor cells
Target tumor medicine.
Nitrogen-containing heterocycle compound, its pharmaceutically acceptable salt, enantiomter, diastereo-isomerism that the present invention is provided
Body, dynamic isomer, solvate, polymorph or its prodrug, wherein, formula such as formula I or the formula I ' of nitrogen-containing heterocycle compound
It is shown:
In formula I or formula I ':
R1、R2、R3、R4In hydrogen, halogen, cyano group, hydroxyl, amino and substituted or unsubstituted C1-C6 alkyl
Any one, and R1、R2、R3、R4In any two group can be formed 3-10 unit ring system;
M1、M2、M3Independently selected from CRa or N, and M1、M2And M3In at least one be N;Ra is hydrogen, halogen, cyano group, takes
One kind in generation or unsubstituted C1-C6 alkyl and substituted or unsubstituted C3-C8 cycloalkyl;
W is selected from any one of following radicals:Substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenes
Base, unsubstituted or halo 4~8 yuan of alkynyl group, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 4-8 units
Heterocyclic radical, the aromatic radical or heteroaryl, substituted carbonyl, substituted sulphonyl, substituted or unsubstituted amino of 5-10 units, wherein, institute
Heterocyclic radical is stated comprising 1-3 selected from the hetero atom in N, O, S, P and B;
At least one substitution base that described one or more groups being substituted by group are selected from the following group is replaced:Halogen
Element, hydroxyl, amino, cyano group, unsubstituted or halo C1-C8 alkyl, unsubstituted or halo C3-C8 cycloalkyl, it is unsubstituted or
The C1-C8 alkoxyl of halo, unsubstituted or halo C2-C6 alkenyls, unsubstituted or halo C2-C6 alkynyls, unsubstituted or halogen
The C2-C6 acyl groups in generation, unsubstituted or halo 5~8 yuan of aryl, unsubstituted or halo 5~8 unit's heteroaryls, unsubstituted or halogen
4~8 yuan of saturated heterocyclics in generation, unsubstituted or halo 4~8 yuan of carbocyclic rings;Wherein, the heteroaryl comprising 1-3 selected from N, O and
Hetero atom in S, the heterocycle includes the 1-3 hetero atom selected from N, O and S;
In formula I ', L is selected from any one of following radicals:- CR ' R "-,-O- ,-NR '-and-CR '=, wherein R ' and R " it is each
Any one from independently being hydrogen, fluorine, deuterium, C1-C6 alkyl and C1-C6 Heterocyclylalkyls, or wherein adjacent R ' and R " shape
Circlewise group.
Compound shown in above-mentioned formula I or its enantiomter, diastereoisomer, dynamic isomer, solvate, polycrystalline
Type thing, prodrug or pharmaceutically acceptable salt;Or
Compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorphic
In thing, prodrug or pharmaceutically acceptable salt:R1、R2、R3、R4Concretely hydrogen.
Compound shown in above-mentioned formula I or its enantiomter, diastereoisomer, dynamic isomer, solvate, polycrystalline
Type thing, prodrug or pharmaceutically acceptable salt;Or
Compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorphic
In thing, prodrug or pharmaceutically acceptable salt:Compound shown in formula I or compound shown in formula I ' meet it is following 1) and/or 2):
1) in formula I or formula I ', M1、M2Independently selected from CH or N, and M1And M2In at least one be N;M3Selected from C-F, C-
CF3, any one in C-Cl, CH and N;
2) in formula I or formula I ', W is selected from any one in following radicals:Substituted or unsubstituted C1-C6 alkyl or cycloalkanes
Base, substituted or unsubstituted 4-10 circle heterocycles, substituted or unsubstituted 4-10 unit's cycloalkyl and substituted or unsubstituted 4-10 units
Volution or bridged ring that Heterocyclylalkyl is formed;W is specially any one in substituted or unsubstituted following radicals:Pentamethylene, hexamethylene
Alkane, nafoxidine ring, tetrahydrofuran ring, piperidine ring, tetrahydrochysene piperidine ring, piperazine ring, morpholine ring, pyrazole ring, indazole ring, phenyl ring
Or pyridine ring;
The substitution refers at least one for replacing base independently selected from following radicals:Halogen, hydroxyl, cyano group, amino, alkane
Base, alkyl monosubstituted amino, dialkyl amido), cycloalkyl, heterocyclic radical, alkoxy, hydroxy alkyl, alkoxyalkyl, hydroxy alkoxy base
Alkyl, aminoalkyl, dialkyl aminoalkyl, alkoxycarbonylamino, cycloalkyl-alkyl, cycloheteroalkylalkyl, aralkyl,
Alkyl-cycloalkyl, naphthene base carbonyl, alkoxy carbonyl, alkoxy carbonyl heterocyclic radical, (alkoxy carbonyl group) (alkyl) amino, (alcoxyl
Base alkyl) (alkyl) amino.
Compound shown in above-mentioned formula I or its enantiomter, diastereoisomer, dynamic isomer, solvate, polycrystalline
Type thing, prodrug or pharmaceutically acceptable salt;Or
Compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorphic
In thing, prodrug or pharmaceutically acceptable salt:
Concretely in compound shown in the compound to-w of formula I shown in the-a of following formula I any one of compound shown in formula I:
Concretely in the-a of the following formula I ' to-c of formula I ' any one of compound shown in formula I ':
Invention further provides compound shown in a kind of formula I or its enantiomter, diastereoisomer, mutually
Tautomeric, solvate, polymorph, prodrug or pharmaceutically acceptable salt;Or
Compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorphic
The method of thing, prodrug or pharmaceutically acceptable salt, comprises the following steps:
(1) by compound shown in formula IV and compound shown in formula V, in transition-metal catalyst and/or acid/base (acid/base
Represent acid or alkali) exist under conditions of be coupled, obtain compound shown in formula III;
In formula IV, X and LG is each independently leaving group, and selected from halogen, sulphonic acid ester, boric acid and borate in appoint
It is a kind of;
In formula III, the definition of X is with formula IV;M1、M2And M3Definition with formula I or Formulas I ';
(2) compound shown in formula III and compound shown in formula II or compound shown in formula II ' transition-metal catalyst and/
Or acid/base (acid/base represent acid or alkali) exist under conditions of be coupled, obtain compound shown in Formulas I or Formulas I ' shown in chemical combination
Thing;
In formula II, the definition of R1, R2, R3, R4, L and W is with formula I;In formula II ', R1、R2、R3、R4, L and W the same formula of definition
Ⅰ’。
In above-mentioned preparation method, in step (1) or step (2),
The coupling reaction is carried out in a solvent, and the solvent is selected from water, methyl alcohol, ethanol, isopropanol, ethylene glycol, N-
Methyl pyrrolidone, dimethyl sulfoxide (DMSO), tetrahydrofuran, toluene, dichloromethane, 1,2- dichloroethanes, acetonitrile, N, N- dimethyl methyls
At least one in acid amides, DMAC N,N' dimethyl acetamide and dioxane;
The transition-metal catalyst is selected from three (dibenzalacetone) two palladium, tetrakis triphenylphosphine palladium, palladium, chlorination
Palladium, dichloro two (triphenylphosphine) palladium, trifluoracetic acid palladium, triphenylphosphine palladium acetate, [double (diphenylphosphino) ferrocene of 1,1'-] two
At least one in palladium bichloride, double (three adjacent benzyl phosphines) palladium chlorides and 1,2- bis- (diphenylphosphino) ethane palladium chloride;
The catalyst ligand is selected from tri-butyl phosphine, tetrafluoro boric acid tri-butyl phosphine, tri-n-butyl phosphine, triphenylphosphine, three pairs of benzene first
At least one in the adjacent benzyl phosphine of base phosphine, tricyclohexyl phosphine and three;
The alkali is inorganic base or organic base;The inorganic base is selected from sodium hydride, potassium hydroxide, sodium acetate, potassium acetate, uncle
In butanol potassium, sodium tert-butoxide, potassium fluoride, cesium fluoride, potassium phosphate, potassium carbonate, saleratus, sodium carbonate and sodium acid carbonate at least
It is a kind of;The organic base be selected from pyridine, triethylamine, DIPEA, the carbon of 1,8- diazabicylos [5.4.0] 11-
At least one in 7- alkene, the silicon substrate lithium of hexamethyl two, the silicon substrate sodium of hexamethyl two and lutidines;
The acid selected from hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, formic acid and acetic acid at least
It is a kind of.
Present invention also offers compound shown in formula I or its enantiomter, diastereoisomer, dynamic isomer, molten
Agent compound, polymorph, prodrug or pharmaceutically acceptable salt;Or
Compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorphic
Thing, prodrug or pharmaceutically acceptable salt, are preparing with the work(for suppressing EGFR mutant kinase activities and/or ALK kinase activity
Application in the inhibitor of energy.
Invention further provides a kind of kinase inhibitor, it includes compound shown in formula I or its enantiomter, non-
Enantiomter, dynamic isomer, solvate, polymorph, prodrug or pharmaceutically acceptable salt;Or
Compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorphic
Thing, prodrug or pharmaceutically acceptable salt.
Present invention also offers compound shown in formula I or its enantiomter, diastereoisomer, dynamic isomer, molten
Agent compound, polymorph, prodrug or pharmaceutically acceptable salt;Or
Compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorphic
Thing, prodrug or pharmaceutically acceptable salt, the application in prevention and/or treatment tumour product is prepared.
In above-mentioned application, the tumour can be non-small cell lung cancer, ED-SCLC, adenocarcinoma of lung, lung squamous cancer, pancreas
Cancer, breast cancer, prostate cancer, liver cancer, cutaneum carcinoma, cell carcinoma, gastrointestinal stromal tumor, leukaemia, lymph cancer and nasopharyngeal carcinoma
In any one.
The present invention still further provides a kind of pharmaceutical composition, and it includes:
1) compound or its enantiomter, diastereoisomer, dynamic isomer, solvation shown in the formula I of effective dose
Thing, polymorph, prodrug or pharmaceutically acceptable salt;Or
Compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorphic
Thing, prodrug or pharmaceutically acceptable salt;
2) pharmaceutically acceptable carrier.
The present invention has the advantages that:
The compound with general structure shown in general structure shown in Formulas I or formula I ' that the present invention is provided, can suppress many
Kind of tumour cell, especially can selectively acting in EGFR T790M mutation and the positive lung carcinoma cells of ALK, be that a class is completely newly made
With the Mutiple Targets lung cancer therapy medicine of mechanism.
Term in the present invention:
Unless otherwise defined, the connotation that otherwise all scientific and technical terminologies have herein and claim theme art technology
The connotation that personnel are generally understood that is identical.Unless otherwise indicated, all patents, patent application, the open material for quoting in full herein
It is integrally incorporated by reference herein.
It should be understood that above-mentioned summary and being specified as hereafter are exemplary and be only used for explaining, without appointing to present subject matter
What is limited.Additionally, term used " including " and other forms, such as it is "comprising", " containing " and " containing " and non-limiting.
Can be in bibliography (including Carey and Sundberg " ADVANCED ORGANIC CHEMISTRY 4TH
ED. " Vols.A (2000) and B (2001), Plenum Press, New York) in find definition to standard chemistry terms.
Unless otherwise stated, using the conventional method in the range of art technology, such as mass spectrum, NMR, IR and UV/VIS spectroscopic methodology and
Pharmacological method.Unless proposition is specifically defined, otherwise herein in analytical chemistry, Synthetic Organic Chemistry and medicine and pharmaceutical chemistry
Relevant description in the term that uses be known in the art.In chemical synthesis, chemical analysis, medicine preparation, preparation and can pass
Send, and to using standard technique in the treatment of patient.For example, using manufacturer to the operation instruction of kit, or according to
Mode well known in the art or explanation of the invention are implemented to react and are purified.Generally can according in this specification quote and
Description in multiple summary and more specific document of discussion, according to conventional method well known in the art implement above-mentioned technology and
Method.In this manual, can by those skilled in the art select group and its substitution base with provide stabilization structure division and
Compound.
When the conventional chemical formulas by writing from left to right describe substitution base, the substitution base is similarly included from right to left
Write substitution base equivalent in chemistry resulting during structural formula.For example ,-CH2O- is equal to-OCH2-。
Chapter title used herein is only used for the purpose of organizational, and is not necessarily to be construed as the limit to the theme
System.The all documents or literature department point quoted in the application include but is not limited to patent, patent application, article, books, manipulator
Volume and paper, are integrally incorporated herein by reference.
Some chemical groups of definition represent carbon atom present in the group previously by symbol is simplified herein
Sum.For example, C1-6 alkyl refers to have 1 to 6 alkyl as defined below of carbon atom altogether.Simplify the carbon in symbol
Total atom number does not include the carbon being likely to be present in the substitution base of the group.
In addition to foregoing, when in the description of the present application and claims, unless otherwise specified, otherwise
Following term has implication as follows.
In this application, term " halogen " refers to fluorine, chlorine, bromine or iodine.
" hydroxyl " refers to-OH groups.
" hydroxy alkyl " refers to the alkyl as defined below replaced by hydroxyl (- OH).
" carbonyl " refers to-C (=O)-group.
" nitro " refers to-NO2。
" cyano group " refers to-CN.
" amino " refers to-NH2。
" substituted amino " refers to by one or two alkyl as defined below, alkyl-carbonyl, aralkyl, heteroaryl alkane
Base substitution amino, for example, alkyl monosubstituted amino, dialkyl amido, alkyl amido, aryl alkyl amino, heteroarylalkyl amino,
(alkoxy carbonyl group) (alkyl) amino, (alkoxyalkyl) (alkyl) amino.
" carboxyl " refers to-COOH.
In this application, (groups such as the alkyl of halogen substitution are used for example in as a part for group or other groups
In), term " alkyl " means only to be made up of carbon atom and hydrogen atom, without unsaturated bond, with such as 1 to 12 (preferably 1
To 8, more preferably 1 to 6) the hydrocarbon chain base of carbon atom and the straight or branched being connected with the remainder of molecule by singly-bound
Group.The example of alkyl include but is not limited to methyl, ethyl, n-propyl, isopropyl, normal-butyl, isobutyl group, sec-butyl, the tert-butyl group,
N-pentyl, 2- methyl butyls, 2,2- dimethyl propyls, n-hexyl, heptyl, 2- methylhexyls, 3- methylhexyls, octyl group, nonyl
With decyl etc..
In this application, as group or a part for other groups, term " alkenyl " (i.e. " alkenyl ") means only
Be made up of carbon atom and hydrogen atom, containing at least one double bond, with such as 2 to 14 (preferably 2 to 10, more preferably 2
To 6) hydrocarbon chain radical of carbon atom and the straight or branched being connected with the remainder of molecule by singly-bound, such as but not limited to
Vinyl, acrylic, pi-allyl, but-1-ene base, but-2-ene base, amyl- 1- alkenyls, amyl- 1,4- dialkylenes etc..
In this application, as group or a part for other groups, term " alkynyl " (i.e. " alkynyl group ") means only
Be made up of carbon atom and hydrogen atom, containing at least one 3 keys and one or more optional double bonds, with such as 2 to 14
(preferably 2 to 10, more preferably 2 to 6) carbon atom and the straight chain that is connected with the remainder of molecule by singly-bound or branch
The hydrocarbon chain radical of chain, such as but not limited to acetenyl, propyl- 1- alkynyls, butyl- 1- alkynyls, amyl- 1- alkene -4- alkynyls etc..
In this application, as group or a part for other groups, term " cycloalkyl " mean only by carbon atom and
The non-aromatic monocyclic or multi-ring alkyl of the stabilization of hydrogen atom composition, it may include fused ring system, bridged-ring system or volution body
System, with 3 to 15 carbon atoms, preferably with 3 to 10 carbon atoms, more preferably with 3 to 8 carbon atoms, and it is saturation
Or it is unsaturated and can be connected with the remainder of molecule by singly-bound via any suitable carbon atom.Unless another in this specification
Specialize outward, the carbon atom in cycloalkyl can optionally be oxidized.The example of cycloalkyl includes but is not limited to cyclopropyl, ring
Butyl, cyclopenta, cyclopentenyl, cyclohexyl, cyclohexenyl group, cyclohexadienyl, suberyl, cyclooctyl, 1H- indenyls, 2,3- bis-
Hydrogenated indenyl, 1,2,3,4- tetrahydro-naphthalenyls, 5,6,7,8- tetrahydro-naphthalenyls, 8,9- dihydro -7H- benzo ring heptene -6- bases, 6,7,
8,9- tetrahydrochysene -5H- benzocycloheptas alkenyl, 5,6,7,8,9,10- hexahydros-benzo ring octenyl, fluorenyl, two rings [2.2.1] heptyl,
7,7- dimethyl-two ring [2.2.1] heptyl, two rings [2.2.1] heptenyl, two rings [2.2.2] octyl group, two rings [3.1.1] heptyl,
Two rings [3.2.1] octyl group, two rings [2.2.2] octenyl, two rings [3.2.1] octenyl, adamantyl, octahydro -4,7- methylene -
1H- indenyls and octahydro -2,5- methylene-pentalene base etc..
In this application, as group or a part for other groups, term " heterocyclic radical " means by 2 to 14 carbon originals
3 yuan to 20 yuan non-aromatic cyclic groups of the stabilization that son and 1 to 6 hetero atom selected from nitrogen, phosphorus, oxygen and sulphur are constituted.Remove
Specialized in addition in non-this specification, otherwise heterocyclic radical can be the member ring systems of monocyclic, bicyclic, three rings or more ring, and it can
Including fused ring system, bridged-ring system or spiro ring system;Nitrogen, carbon or sulphur atom in its heterocyclic radical are optionally oxidized;Nitrogen
Atom is optionally quaternized;And heterocyclic radical can be partially or completely saturation.Heterocyclic radical can be via carbon atom or miscellaneous original
Son is simultaneously connected by singly-bound with molecule remainder.In the heterocyclic radical comprising condensed ring, one or more rings can be hereafter institute
The aryl or heteroaryl of definition, it with the tie point of molecule remainder is non-aromatic annular atom that condition is.With regard to mesh of the invention
For, heterocyclic radical is preferably comprising 1 to 34 yuan to 11 yuan nonaro-maticity list selected from the heteroatomic stabilization of nitrogen, oxygen and sulphur
Ring, bicyclic, bridged ring or spiro-cyclic groups, more preferably comprising 1 to 34 yuan to 8 of the heteroatomic stabilization for being selected from nitrogen, oxygen and sulphur
First non-aromatic monocyclic, bicyclic, bridged ring or spiro-cyclic groups.The example of heterocyclic radical is included but is not limited to:Pyrrolidinyl, morpholinyl,
Piperazinyl, homopiperazine base, piperidyl, tetrahydrochysene piperidyl, thio-morpholinyl, 2,7- diaza-spiros [3.5] nonane -7- bases, 2- oxygen
Miscellaneous -6- aza-spiros [3.3] heptane -6- bases, 2,5- diazas-bicyclic [2.2.1] heptane -2- bases, azetidinyl, pyrans
Base, THP trtrahydropyranyl, thiapyran base, tetrahydrofuran base, oxazinyls, dioxy cyclopenta, tetrahydro isoquinolyl, Decahydroisoquinolinpreparation base,
Imidazolinyl, imidazolidinyl, quinolizine base, thiazolidinyl, isothiazole alkyl, isoxazole alkyl, indolinyl, octahydro indoles
Base, octahydro isoindolyl, pyrrolidinyl, pyrazolidinyl, phthaloyl imino etc..
In this application, as group or a part for other groups, term " aryl " (i.e. " aromatic radical ") means tool
There is the conjugated hydrocarbon member ring systems group of 6 to 18 carbon atoms (preferably with 6 to 10 carbon atoms).For purposes of the invention,
Aryl can be the member ring systems of monocyclic, bicyclic, three rings or more ring, can also be thick with cycloalkyl defined above or heterocyclic radical
Close, condition is that aryl is connected by singly-bound via the atom on aromatic rings with the remainder of molecule.The example of aryl include but
It is not limited to phenyl, naphthyl, anthryl, phenanthryl, fluorenyl, 2,3- dihydro -1H- isoindolyls, 2- benzoxazolinones, 2H-1,4- benzene
Bing oxazines -3 (4H) -one -7- bases etc..
In this application, term " aryl alkyl " refers to the alkane defined above replaced by aryl defined above
Base.
In this application, as group or a part for other groups, term " heteroaryl " means there is 1 to 15 in ring
Individual carbon atom (preferably with 1 to 10 carbon atom) and 1 to 6 heteroatomic 5 yuan to 16 yuan conjugate ring selected from nitrogen, oxygen and sulphur
It is group.Unless specialized in addition in this specification, otherwise heteroaryl can be the ring body of monocyclic, bicyclic, three rings or more ring
System, can also condense with cycloalkyl defined above or heterocyclic radical, and condition is that heteroaryl passes through via the atom on aromatic rings
Singly-bound is connected with the remainder of molecule.Nitrogen, carbon or sulphur atom in heteroaryl are optionally oxidized;Nitrogen-atoms is optionally
It is quaternized.For purposes of the invention, heteroaryl is preferably the heteroatomic stabilization selected from nitrogen, oxygen and sulphur comprising 1 to 5
5 yuan to 12 yuan aromatic radicals, more preferably comprising 1 to 45 yuan to 10 of heteroatomic stabilization selected from nitrogen, oxygen and sulphur
First aromatic radical or comprising 1 to 3 heteroatomic 5 yuan to 10 yuan aromatic radical selected from nitrogen, oxygen and sulphur.Heteroaryl
Example include but is not limited to thienyl, imidazole radicals, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyls, pyridine radicals,
Pyrimidine radicals, pyrazinyl, pyridazinyl, benzimidazolyl, benzopyrazoles base, indyl, furyl, pyrrole radicals, triazolyl, tetrazolium
Base, triazine radical, indolizine base, isoindolyl, indazolyl, iso indazolyl, purine radicals, quinolyl, isoquinolyl, phenodiazine naphthyl, naphthalene
Piperidinyl, quinoxalinyls, pteridyl, carbazyl, carboline base, phenanthridinyl, phenanthroline, acridinyl, phenazinyl, isothiazolyl, benzene
It is benzothiazolyl, benzothienyl, oxatriazoles base, cinnolines base, quinazolyl, thiophenyl, indolizine base, phenanthrolene base, different
Oxazolyl, phenoxazine groups, phenothiazinyl, 4,5,6,7- tetrahydro benzos [b] thienyl, naphtho- pyridine radicals, [1,2,4] triazol
[4,3-b] pyridazine, [1,2,4] triazol [4,3-a] pyrazine, [1,2,4] triazol [4,3-c] pyrimidine, [1,2,4] triazol
[4,3-a] pyridine, imidazo [1,2-a] pyridine, imidazo [1,2-b] pyridazine, imidazo [1,2-a] pyrazine etc..
In this application, term " heteroaryl alkyl " refer to by heteroaryl defined above replaced it is defined above
Alkyl.
In this application, term " Heterocyclylalkyl " refer to by heterocyclic radical defined above replaced it is defined above
Alkyl.
In this application, " optional " or " optionally " represents that the event or situation of then description may be likely to not
Occur, and the description includes the situation that the event or situation occur and do not occur simultaneously.For example, " aryl being optionally substituted "
Represent that aryl substituted or unsubstituted, and the description includes substituted aryl and unsubstituted aryl simultaneously.
During terms used herein " part ", " structure division ", " chemical part ", " group ", " chemical group " refer to molecule
Specific fragment or functional group.Chemical part is typically considered the chemical entities being embedded or attached on molecule.
" stereoisomer " refers to be made up of same atoms, is bonded by identical key, but with different three-dimensional structures
Compound.The present invention will cover various stereoisomers and its mixture.
When alkene double bond is contained in compound of the invention, unless otherwise stated, compound of the invention is intended to bag
Containing E- and Z- geometric isomers.
" dynamic isomer " refers to that proton is formed from an atom transfer of molecule to another atom of identical molecule
Isomers.All tautomeric forms of compound of the invention also will be contained in the scope of the present invention.
Compound of the invention or its pharmaceutically acceptable salt may contain one or more asymmetric carbon atoms, and therefore
Enantiomter, diastereoisomer and other stereoisomeric forms in any ratio can be produced.Each asymmetric carbon atom can be based on three-dimensional
Learn and be defined as (R)-or (S)-.It is contemplated that including all possible isomers, and its racemic modification and optical voidness
Form.The preparation of compound of the invention racemic modification, diastereoisomer or enantiomter can be selected as raw material or
Intermediate.Optically active isomers can be prepared using chiral synthon or chiral reagent, or be entered using routine techniques
Row splits, for example with methods such as crystallization and chiral chromatograms.
The routine techniques of preparation/separation individual isomeric includes being synthesized by the chirality of suitable optical voidness precursor, or makes
With such as chiral hplc resolution of racemic body (or racemic modification of salt or derivative), Gerald is see, for example,
Gübitz and Martin G.Schmid(Eds.),Chiral Separations,Methods and Protocols,
Methods in Molecular Biology,Vol.243,2004;A.M.Stalcup,Chiral Separations,
Annu.Rev.Anal.Chem.3:341-63,2010;Fumiss et al.(eds.),VOGEL'S ENCYCLOPEDIA OF
PRACTICAL ORGANIC CHEMISTRY 5.sup.TH ED.,Longman Scientific and Technical
Ltd.,Essex,1991,809-816;Heller,Acc.Chem.Res.1990,23,128.
In this application, term " pharmaceutically acceptable salt " includes pharmaceutically acceptable acid-addition salts and pharmaceutically may be used
The base addition salts of receiving.
" pharmaceutically acceptable acid-addition salts " be refer to retain free alkali biological effectiveness and without other side effects
, the salt formed with inorganic acid or organic acid.Inorganic acid salt includes but is not limited to hydrochloride, hydrobromate, sulfate, nitric acid
Salt, phosphate etc.;Acylate includes but is not limited to formates, acetate, 2,2- DCAs, trifluoroacetate, propionic acid
Salt, caproate, caprylate, caprate, undecylenate, glycollate, gluconate, lactate, sebacate, adipic acid
Salt, glutarate, malonate, oxalates, maleate, succinate, fumarate, tartrate, citrate, palm
Hydrochlorate, stearate, oleate, cinnamate, laruate, malate, glutamate, pyroglutamate, aspartic acid
Salt, benzoate, mesylate, benzene sulfonate, tosilate, alginate, ascorbate, salicylate, 4- ammonia
Base salicylate, napadisilate etc..These salt can be prepared by method known in the art.
" pharmaceutically acceptable base addition salts " be refer to keep free acid biological effectiveness and without other side effects
And salt that inorganic base or organic base are formed.Salt derived from inorganic base includes but is not limited to sodium salt, sylvite, lithium salts, ammonium
Salt, calcium salt, magnesium salts, molysite, zinc salt, mantoquita, manganese salt, aluminium salt etc..Preferred inorganic salts are ammonium salt, sodium salt, sylvite, calcium salt and magnesium
Salt.Salt derived from organic base includes but is not limited to following salt:Primary amine class, secondary amine class and tertiary amines, substituted amine, bag
Include natural substituted amine, cyclic amine and deacidite, such as ammonia, isopropylamine, trimethylamine, diethylamine, three
Ethamine, tripropyl amine (TPA), monoethanolamine, diethanol amine, triethanolamine, dimethylethanolamine, DMAE, 2- lignocaine second
Alcohol, dicyclohexyl amine, lysine, arginine, histidine, caffeine, procaine, choline, glycine betaine, ethylenediamine, gucosamine,
Methyl glucose osamine, theobromine, purine, piperazine, piperidines, N-ethylpiperidine, polyamino resin etc..Preferred organic base includes isopropyl
Amine, diethylamine, monoethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.These salt can be by method known in the art
Prepare.
" polymorph " refers to some compounds of the invention in the solid state due to there is two or more not
The different solid crystal phases produced with molecules align.Some compounds of the invention there may be more than one crystal formation, this hair
It is bright to be intended to include various crystal formations and its mixture.
Generally, crystallization effect can produce the solvate of the compounds of this invention.Term " the solvation used in the present invention
Thing " refers to the aggregation comprising one or more the compounds of this invention molecules Yu one or more solvent molecules.Solvent can be
Water, solvate in this case is hydrate.Or, solvent can be organic solvent.Therefore, compound of the invention can be with
Exist with hydrate, including monohydrate, dihydrate, semihydrate, times semihydrate, trihydrate, tetrahydrate etc., with
And corresponding solvation form.The compounds of this invention can form real solvate, but in some cases, it is also possible to only protect
Indefinite water or water are stayed plus the mixture of the indefinite solvent in part.Compound of the invention can react in a solvent or from
Precipitation or crystallized out in solvent.The solvate of the compounds of this invention is also contained within the scope of the present invention.
Present invention additionally comprises the prodrug of above-claimed cpd.In this application, term " prodrug " expression can be in physiological conditions
Compound lower or that bioactive compound of the invention is converted to by solvolysis.Therefore, term " prodrug " refers to
The pharmaceutically acceptable metabolic precursor thereof of compound of the invention.When being given in need individual, prodrug can not have
Activity, but reactive compound of the invention is converted in vivo.Prodrug generally rapid conversion in vivo, and produce of the invention
Parent compound, for example, realized by hydrolyzing in blood.Prodrug compound generally provides molten in mammalian organism
The advantage of Xie Du, histocompatbility or sustained release.Prodrug includes known amino protecting group and carboxyl-protecting group.Specific prodrug system
Preparation Method can refer to Saulnier, M.G., et al., Bioorg.Med.Chem.Lett.1994,4,1985-1990;
Greenwald,R.B.,et al.,J.Med.Chem.2000,43,475。
In this application, " pharmaceutical composition " refers to the generally receiving of the compounds of this invention and this area for biology to be lived
Property compound is delivered to the preparation of the medium of mammal (such as people).The medium includes pharmaceutically acceptable carrier.Medicine
The purpose of composition is to promote the administration of organism, absorption beneficial to active component and then plays bioactivity.
Terms used herein " pharmaceutically acceptable " refers to the bioactivity or property for not influenceing the compounds of this invention
Material (such as carrier or diluent), and relative nontoxic, the i.e. material can be applied to individuality without causing bad biological respinse
Or interacted with any component included in bad mode and composition.
In this application, " pharmaceutically acceptable carrier " includes but is not limited to any be permitted by related government administration section
Can be acceptable adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, the dye used for the mankind or domestic animal
Material/colouring agent, flavouring, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifying agent.
" tumour " of the present invention, " cell proliferative disorder relevant disease " etc. include but is not limited to leukaemia, gastro-intestinal stromal
Knurl, histiocytic lymphoma, non-small cell lung cancer, ED-SCLC, cancer of pancreas, lung squamous cancer, adenocarcinoma of lung, breast cancer, prostatitis
Gland cancer, liver cancer, cutaneum carcinoma, cell carcinoma, cervical carcinoma, oophoroma, intestinal cancer, nasopharyngeal carcinoma, the cancer of the brain, osteocarcinoma, cancer of the esophagus, melanin
The diseases such as knurl, kidney, carcinoma of mouth.
Terms used herein " prevention ", " prevention " and " preventing " includes sufferer is reduced disease or illness generation or evil
The possibility of change.
Term " treatment " the used herein synonym similar with other includes following meanings:
I () prevention disease or illness occur in mammal, particularly when this kind of mammal be susceptible to the disease or
Illness, but when being not yet diagnosed as having suffered from the disease or illness;
(ii) suppress disease or illness, that is, contain that it develops;
(iii) disease or illness are alleviated, i.e. the state of the disease or illness is disappeared;Or
(iv) disease or the symptom caused by illness are mitigated.
Term " effective dose ", " therapeutically effective amount " or " pharmacy effective dose " used herein refers to take metapedes with certain
At least one medicament or the amount of compound of one or more symptoms of the treated disease of alleviation or illness in degree.Its result
Can be sign, symptom or the cause of disease abatement and/or alleviation, or biosystem it is any other needed for change.For example, for controlling
" effective dose " treated is the composition comprising compound disclosed herein needed for clinically providing significant remission effect
Amount.The technology of such as dose escalation trial can be used to determine the effective dose being suitable in any individual case.
Terms used herein " taking ", " administration ", " administration " etc. are to refer to be delivered to compound or composition carry out
The method in the required site of biological agent.These methods include but is not limited to oral route, through intraduodenal routes, parenteral note
Penetrate (including intravenous, subcutaneous, intraperitoneal, intramuscular, intra-arterial injection or infusion), local administration and per rectum administration.This area
Can be used for the application technique of Compounds and methods for described herein known to technical staff, such as in Goodman and Gilman, The
Pharmacological Basis of Therapeutics,current ed.;Pergamon;and Remington's,
Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, discuss in Pa
Those.In preferred embodiments, the compound and composition being discussed herein are by Orally administered.
Term " drug regimen " used herein, " drug combination ", " drug combination ", " apply other treatment ", " apply it
Its therapeutic agent " etc. refers to the drug therapy obtained by mixing or combining more than one active component, and it includes active component
Fixation and non-fixed Combination.Term " fixed Combination " refers to be administered simultaneously to patient in the form of single entity or single formulation
At least one compound as herein described and at least one collaboration medicament.Term " not fixed Combination " refers to the shape of corpus separatum
Formula is administered simultaneously to patient, share or at least one compound as herein described is sequentially applied with variable interval time and at least
One kind collaboration preparation.These are also applied in HAART, such as using three or more active component.
It should also be appreciated by one skilled in the art that in method discussed below, midbody compound functional group may need
To be protected by appropriate protection group.Such functional group includes hydroxyl, amino, sulfydryl and carboxylic acid.Suitable hydroxyl protecting group bag
Include trialkylsilkl or diarylalkyl-silyl (such as t-butyldimethylsilyl, tert-butyl diphenyl first
Silylation or trimethyl silyl), THP trtrahydropyranyl, benzyl etc..The protection group of suitable amino, amidino groups and guanidine radicals includes uncle
Butoxy carbonyl, benzyloxycarbonyl group etc..Suitable sulfhydryl protected base includes-C (O)-R " (wherein R " be alkyl, aryl or aralkyl),
To methoxy-benzyl, trityl etc..Suitable carboxyl-protecting group includes alkyl, aryl or aralkyl esters.
Protection group can be introduced and removed according to standard technique well known by persons skilled in the art and as described herein.Protect
The use for protecting base is specified in Greene, T.W. and P.G.M.Wuts, Protective Groups in Organi
Synthesis, (1999), 4th Ed., in Wiley.Protection group can also be fluoropolymer resin.
Brief description of the drawings
Fig. 1 is the route map of compound shown in synthesis type II or compound shown in formula II '.
Fig. 2 is the route map of compound shown in synthesis type III.
Fig. 3 is the route map of compound shown in synthesis type I or compound shown in formula I '.
Specific embodiment
Experimental technique used in following embodiments is conventional method unless otherwise specified.
Material used, reagent etc. in following embodiments, unless otherwise specified, commercially obtain.
Intermediate in following embodiments is prepared in accordance with the following steps, wherein, compound or formula II ' shown in formula II
Shown compound synthesizes according to the route map of Fig. 1;Compound shown in formula III synthesizes according to the route map of Fig. 2;Compound shown in formula I
Or compound shown in formula I ' synthesizes according to the route map of Fig. 3.
Intermediate 1:
Bromo- 2, the 3- Dihydrobenzofuranes -7- amine (2.05g, 9.58mmol) of compound 4- are dissolved in 1,2- dichloroethanes
In (20mL), after stirring, be slowly dropped into (~30min) to be previously heated to reflux state mCPBA (7.80g,
In 1,2- dichloroethanes (60mL) 38.2mmol), continue back flow reaction 2h, raw material disappears.Solvent is evaporated off, EA is added
(50mL), saturation Na2S2O3(aq) wash (30mL × 3), 0.5M NaOH (aq) are washed (30mL × 3), column chromatography (P/E=5:1) divide
From faint yellow solid 1.60g is obtained, yield is 68%.Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):7.84 (d, J=
8.8Hz, 1H), 7.11 (d, J=8.8Hz, 1H), 4.92 (t, J=8.8Hz, 2H), 3.35 (t, J=8.8Hz, 2H)
Intermediate 2:
Compound 4- bromine 7- nitro -2,3- Dihydrobenzofuranes (500mg, 2.05mmol) are dissolved in toluene (30mL)
In, sequentially add Pd (OAc)2(50mg, 0.21mmol), DavePhos (161mg, 0.41mmol) and K3PO4(1.31g,
6.15mmol,6mL H2O), after stirring, 4- dimethylamino piperidines (789mg, 6.15mmol) is added, under argon gas protection, is returned
Stream reaction 20h, raw material disappears.Room temperature is cooled to, solvent is evaporated off, EA (30mL) dissolution residual substance, saturated common salt washing (20mL ×
3) (20mL × 2), are washed, column chromatography (D/M=20:1) yellow solid 500mg is isolated and purified to obtain, yield is 84%.Structure verification
Data are as follows:1H NMR(CDCl3)δ(ppm):7.92 (d, J=8.8Hz, 1H), 6.42 (d, J=8.8Hz, 1H), 4.81 (t, J
=8.4Hz, 2H), 3.71 (d, J=12.0Hz, 2H), 3.20 (t, J=8.4Hz, 2H), 3.04 (m, 1H), 2.90 (t, J=
11.6Hz, 2H), 2.71 (s, 6H), 2.25 (d, J=10.4Hz, 2H), 1.88-1.86 (m, 2H)
Intermediate 3:
Using the identical synthetic method of intermediate 2, with N, N- dimethyl pyrroles are replaced 4- dimethylamino piperidines, are prepared
The yellow solid 130mg of intermediate 3, yield is 76%.Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):7.87(d,J
=9.2Hz, 1H), 6.09 (d, J=9.6Hz, 1H), 4.77-4.67 (m, 2H), 3.77-3.40 (m, 6H), 2.81-2.77 (m,
1H),2.31(s,6H),2.23-2.17(m,1H),1.92-1.87(m,1H).
Intermediate 4:
Using the identical synthetic method of intermediate 2,4- dimethylamino piperidines are replaced with N-Boc piperazines, prepare centre
The yellow solid 163mg of body 4, yield is 76%.Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):7.93 (d, J=
9.2Hz, 1H), 6.42 (d, J=9.2Hz, 1H), 4.81 (t, J=8.4Hz, 2H), 3.57 (t, J=4.8Hz, 4H), 3.24-
3.17(m,6H),1.49(s,6H).
Intermediate 5:
Using the identical synthetic method of intermediate 2,4- dimethylamino piperidines are replaced with N methyl piperazine, prepare centre
The yellow solid 84mg of body 5, yield is 52%.Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):7.92 (d, J=
9.2Hz, 1H), 6.43 (d, J=9.2Hz, 1H), 4.80 (t, J=8.8Hz, 2H), 3.27 (t, J=4.8Hz, 4H), 3.21 (t,
J=8.8Hz, 2H), 2.55 (t, J=4.8Hz, 4H), 2.36 (s, 3H)
Intermediate 6:
Using the identical synthetic method of intermediate 2, replaced with 1-methyl-4- (piperidin-4-yl) piperazine
4- dimethylamino piperidines, prepare the yellow powdery solid 148mg of intermediate 6, and yield is 69%.Structure verification data are such as
Under:1H NMR(CDCl3)δ(ppm):7.90 (d, J=9.2Hz, 1H), 6.41 (d, J=9.2Hz, 1H), 4.79 (t, J=
8.4Hz, 2H), 3.67 (d, J=12.8Hz, 2H), 3.20 (t, J=8.8Hz, 2H), 2.88 (t, J=12.0Hz, 2H), 2.69
(brs, 4H), 2.56 (brs, 4H), 2.49-2.43 (m, 1H), 2.35 (s, 3H), 1.98 (d, J=11.6Hz, 2H), 1.68-
1.58(m,2H).
Intermediate 7:
Intermediate 1 (200mg, 0.82mmol) is dissolved in toluene (10mL), Pd (OAc) is sequentially added2(20mg,
0.08mmol), DavePhos (65mg, 0.16mmol) and K3PO4(520mg, 2.46mmol, 2mL H2O), after stirring, plus
Enter tert-butyl4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -5,6-
Dihydropyridine-1 (2H)-carboxylate (760mg, 2.46mmol), under argon gas protection, 95 DEG C of reaction 4h, raw material
Disappear.Room temperature is cooled to, solvent is evaporated off, EA (30mL) dissolution residual substance, saturated common salt washes (20mL × 3), washing (20mL ×
2), column chromatography (D/M=10:1) the yellow powdery solid 250mg of intermediate 7, is obtained, yield is 88%.Structure verification data are such as
Under:1H NMR(CDCl3)δ(ppm):7.91 (d, J=8.8Hz, 1H), 6.82 (d, J=8.8Hz, 1H), 5.91 (s, 1H), 4.83
(t, J=8.8Hz, 2H), 4.09 (m, 2H), 3.63 (t, J=8.8Hz, 2H), 3.32 (t, J=8.8Hz, 2H), 2.45 (m,
2H),1.50(s,9H).
Intermediate 8:
Intermediate 7 (190mg, 0.55mmol) is dissolved in DCM (15mL), TFA (625mg, 5.50mmol), room temperature is added
Reaction 3h, raw material disappears.Concentration, obtains the pale yellow powder shape solid 188mg of intermediate 8, and yield is 100%.Structure verification data
It is as follows:1H NMR(CDCl3)δ(ppm):9.07 (brs, 1H), 7.94 (d, J=8.4Hz, 1H), 6.80 (d, J=8.8Hz, 1H),
6.63 (s, 1H), 5.89 (s, 1H), 4.84 (t, J=8.8Hz, 2H), 3.94 (brs, 2H), 3.53 (brs, 2H), 3.31 (t, J
=8.8Hz, 2H), 2.76 (brs, 2H)
Intermediate 9:
Intermediate 8 (170mg, 0.50mmol) is dissolved in THF (10mL) and MeOH (10mL), formalin is added
(120mg, 37%, 1.50mmol) and sodium triacetoxy borohydride (555mg, 2.50mmol), room temperature reaction 2h, raw material disappears
Lose.Concentration, adds EA (30mL), washes (20mL × 3), column chromatography (D/M=20:1) the pale yellow powder shape of intermediate 9, is obtained to consolidate
Body 120mg, yield is 92%.Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):7.90 (d, J=8.8Hz, 1H),
6.83 (d, J=8.8Hz, 1H), 5.91 (m, 1H), 4.81 (t, J=8.8Hz, 2H), 3.33 (t, J=8.8Hz, 2H), 3.16-
(s, the 3H) of 3.15 (m, 2H), 2.69 (t, J=5.6Hz, 2H), 2.53 (m, 2H), 2.44
Intermediate 10:
Using the identical synthetic method of intermediate 2,4- is replaced with 1-Boc-4- (piperidin-4-yl) piperazine
Dimethylamino piperidine, prepares the yellow powdery solid 156mg of intermediate 10, and yield is 58%.Structure verification data are as follows
:1H NMR(CDCl3)δ(ppm):7.90 (d, J=9.2Hz, 1H), 6.41 (d, J=9.6Hz, 1H), 4.79 (t, J=8.8Hz,
2H), 3.67 (d, J=12.4Hz, 2H), 3.45 (m, 4H), 3.20 (t, J=8.8Hz, 2H), 2.87 (t, J=12.0Hz, 2H),
2.53 (m, 4H), 2.46 (m, 2H), 1.94 (d, J=12.0Hz, 2H), 1.66-1.59 (m, 2H)
Intermediate 11:
Intermediate 2 (463mg, 1.59mmol) is dissolved in methanol (20mL), Pd/C (60mg), catalytic hydrogenation is added
3h, raw material disappears.Pd/C is filtered, is concentrated, obtain the off-white powder 410mg of intermediate 11, yield is 99%.Structure verification data are such as
Under:1H NMR(DMSO-d6)δ(ppm):6.38 (d, J=8.0Hz, 1H), 6.24 (d, J=8.4Hz, 1H), 4.45 (t, J=
8.4Hz, 2H), 4.23 (brs, 2H), 3.16 (d, J=12.0Hz, 2H), 3.04 (t, J=8.4Hz, 2H), 2.45-2.50 (m,
2H), 2.31 (m, 7H), 1.85 (d, J=11.6Hz, 2H), 1.55-1.47 (m, 2H)
Intermediate 12:
Using the identical synthetic method of intermediate 11, intermediate 2 is replaced with intermediate 3, obtain the off-white color of intermediate 12 and consolidate
Body 68mg, yield is 96%.Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):6.51 (d, J=8.4Hz, 1H),
6.06 (d, J=8.4Hz, 1H), 4.58-4.50 (m, 2H), 3.41-3.18 (m, 6H), 2.82 (t, J=7.2Hz, 1H), 2.29
(s,6H),2.12-2.11(m,1H),1.88-1.83(m,1H).
Intermediate 13:
Using the identical synthetic method of intermediate 11, intermediate 2 is replaced with intermediate 4, obtain the off-white color of intermediate 13 and consolidate
Body 87mg, yield is 92%.Structure verification data are as follows:1H NMR(DMSO-d6)δ(ppm):6.41 (d, J=8.4Hz, 1H),
6.25 (d, J=8.0Hz, 1H), 4.55 (brs, 2H), 4.46 (t, J=8.4Hz, 2H), 3.40 (m, 4H), 3.07 (t, J=
8.4Hz, 2H), 2.75 (t, J=4.8Hz, 4H), 1.41 (s, 9H)
Intermediate 14:
Using the identical synthetic method of intermediate 11, intermediate 2 is replaced with intermediate 5, obtain the off-white color of intermediate 14 and consolidate
Body 58mg, yield is 100%.Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):6.55 (d, J=8.4Hz, 1H),
6.43 (d, J=8.4Hz, 1H), 4.61 (t, J=8.4Hz, 2H), 3.32 (m, 6H), 3.16 (t, J=8.4Hz, 2H), 2.79
(s,3H),1.28(m,4H).
Intermediate 15:
Using the identical synthetic method of intermediate 11, intermediate 2 is replaced with intermediate 6, obtain the off-white color of intermediate 15 and consolidate
Body 64mg, yield is 78%.Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):6.51 (d, J=8.4Hz, 1H),
6.33 (d, J=8.4Hz, 1H), 4.57 (t, J=8.4Hz, 2H), 3.28 (d, J=12.0Hz, 2H), 3.14 (t, J=8.4Hz,
2H), 2.67-2.52 (m, 10H), 2.37-2.34 (m, 1H), 2.32 (s, 3H), 1.92 (d, J=12.4Hz, 2H), 1.71-
1.61(m,2H).
Intermediate 16:
Using the identical synthetic method of intermediate 11, intermediate 2 is replaced with intermediate 7, obtain the slightly yellow color of intermediate 16
Solid 48mg, yield is 77%.Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):6.85 (d, J=8.4Hz, 1H),
6.54 (d, J=8.0Hz, 1H), 5.71 (s, 1H), 4.55 (t, J=8.8Hz, 2H), 3.55 (brs, 2H), 3.26 (t, J=
8.8Hz, 2H), 3.09-3.07 (m, 2H), 2.63 (t, J=5.6Hz, 2H), 2.51 (m, 2H), 2.40 (s, 3H)
Intermediate 17:
Intermediate 16 (70mg, 0.27mmol) is dissolved in methanol (10mL), Pd/C (15mg), catalytic hydrogenation is added
3h, raw material disappears.Pd/C is filtered, is concentrated, obtain slightly yellow color solid 49mg, yield is 79%.Structure verification data are as follows:1H
NMR(CDCl3)δ(ppm):6.59 (d, J=8.4Hz, 1H), 6.54 (d, J=8.0Hz, 1H), 5.71 (s, 1H), 4.58 (t, J
=8.8Hz, 2H), 3.46 (brs, 2H), 3.18 (t, J=8.8Hz, 2H), 2.98-2.95 (m, 2H), 2.38-2.33 (m, 1H),
2.31(s,3H),2.05-1.98(m,2H),1.81-1.68(m,4H).
Intermediate 18:
Using the identical synthetic method of intermediate 11, intermediate 2 is replaced with intermediate 9, obtains slightly yellow color solid 90mg,
Yield is 90%.Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):6.56-6.54 (m, 2H), 4.59 (t, J=
8.8Hz, 2H), 4.23 (m, 2H), 3.48 (ts, 2H), 3.18 (t, J=8.8Hz, 2H), 2.76 (m, 2H), 2.52-2.49 (m,
1H), 1.74 (d, J=12.4Hz, 2H), 1.64-1.55 (m, 2H)
Intermediate 19:
Using the identical synthetic method of intermediate 11, intermediate 2 is replaced with intermediate 10, obtains off-white powder 55mg,
Yield is 74%.Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):6.51 (d, J=8.4Hz, 1H), 6.33 (d, J=
8.4Hz, 1H), 4.57 (t, J=8.4Hz, 2H), 3.55 (brs, 4H), 3.30 (d, J=11.6Hz, 2H), 3.14 (t, J=
8.4Hz,2H),2.64-2.58(m,7H),1.90(m,2H),1.71(m,2H),1.47(s,9H).
Intermediate 20:
By compound 4,6- dichloro pyrimidines (100mg, 0.60mmol) and 2- (aminophenyl) dimethyl phosphine oxide (51mg,
0.30mmol) it is dissolved in n-butanol (5mL), adds DIEA (116mg, 0.90mmol), back flow reaction 12h, raw material to disappear substantially.
Column chromatography (P/E=1:6) white solid 50mg, is obtained, yield is 56%.Structure verification data are as follows:1H NMR(CDCl3)δ
(ppm):11.02(s,1H),6.62(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.54 (s, 1H), 7.57-7.52 (m, 1H),
7.29-7.23(m,1H),7.14-7.09(m,1H),6.74(s,1H),1.85(s,3H),1.82(s,3H).
Intermediate 21:
Using the identical synthetic method of intermediate 20,4 are replaced with the chloro- 5-FUs (100mg, 0.60mmol) of 2,4- bis-,
6- dichloro pyrimidines, obtain the white solid 50mg of intermediate 21, and yield is 56%.Structure verification data are as follows:1H NMR(CDCl3)δ
(ppm):11.84(s,1H),8.80(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.08 (d, J=2.8Hz, 1H), 7.62-
7.58(m,1H),7.29-7.24(m,1H),7.19-7.14(m,1H),1.87(s,3H),1.84(s,3H).
Intermediate 22:
Using the identical synthetic method of intermediate 20,4,6- dichloros are replaced with 2,4- dichloro pyrimidines (352mg, 2.36mmol)
Pyrimidine, obtains intermediate 22 and obtains white solid 120mg, and yield is 36%.Structure verification data are as follows:1H NMR(CDCl3)δ
(ppm):11.22(s,1H),8.69(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.14 (d, J=5.6Hz, 1H), 7.59-
7.55 (m, 1H), 7.27-7.25 (m, 1H), 7.14-7.10 (m, 1H), 6.58 (d, J=5.6Hz, 1H), 1.85 (s, 3H),
1.82(s,3H).
Intermediate 23 and 24:
Using the identical synthetic method of intermediate 20, with the chloro- 5- trifluoromethyl pyrimidines (386mg, 1.78mmol) of 2,4- bis-
4,6- dichloro pyrimidines are replaced, the mixture of intermediate 23 and 24 is obtained:White solid 210mg, yield is 68%.Structure verification data
It is as follows:1H NMR(CDCl3)δ(ppm):11.67(s,1H),11.28(s,0.5H),8.65-8.62(m,1H),8.59(s,1H),
8.49-8.46(m,1H),7.61-7.54(m,1.5H),7.34-7.22(m,2H),7.15-7.12(m,1H),1.86(s,3H),
1.85(s,1.5H),1.83(s,3H),1.81(s,1.5H).
Intermediate 25:
Using the identical synthetic method of intermediate 20, replaced with the chloro-1,3,5-triazines of 2,4- bis- (267mg, 1.78mmol)
4,6- dichloro pyrimidines, obtain intermediate 25:White solid 150mg, yield is 60%.Structure verification data are as follows:1H NMR
(DMSO-d6)δ(ppm):11.81(brs,1H),8.63(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.57 (s, 1H), 7.60
(t, J=8.0Hz, 1H), 7.33-7.27 (m, 1H), 7.22-7.18 (m, 1H), 1.88 (s, 3H), 1.85 (s, 3H)
Intermediate 26:
Using the identical synthetic method of intermediate 20,4,6- bis- is replaced with 2,4,5- trichloropyrimidines (866mg, 4.72mmol)
Chlorine pyrimidine, obtains intermediate 26:Off-white powder 483mg, yield is 65%.Structure verification data are as follows:1H NMR(DMSO-d6)δ
(ppm):11.55(brs,1H),8.67(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.22 (s, 1H), 7.60 (t, J=
8.4Hz,1H),7.32-7.28(m,1H),7.20-7.18(m,1H),1.86(s,3H),1.83(s,3H).
Embodiment 1:
Intermediate 11 (25mg, 0.10mmol) and intermediate 20 (35mg, 0.12mmol) are dissolved in iPrOH (1mL), plus
Enter concentrated hydrochloric acid (24mg, 0.25mmol), microwave reaction (250w, 130 DEG C, 120min, 300psi).Room temperature is cooled to, EA is added
(20mL), saturated sodium bicarbonate (aq) is washed (20mL × 3), saturated common salt washing (20mL × 3), column chromatography (D/M/Et3N=10:
1:0.02) embodiment 1, is obtained:Off-white powder 48mg, yield is 71%.
Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):10.01(s,1H),8.46(dd,J1=8.4Hz, J2
=4.4Hz, 1H), 8.35 (s, 1H), 7.47 (t, J=7.6Hz, 1H), 7.23-7.15 (m, 2H), 7.02-6.98 (m, 1H),
6.45 (d, J=8.8Hz, 1H), 6.35 (s, 1H), 5.87 (s, 1H), 4.60 (t, J=8.8Hz, 2H), 3.40 (d, J=
12.0Hz, 2H), 3.20 (t, J=8.8Hz, 2H), 2.67 (t, J=12.0Hz, 2H), 2.33 (s, 6H), 2.29-2.23 (m,
1H), 1.93 (d, J=12.0Hz, 2H), 1.80 (s, 3H), 1.74 (s, 3H), 1.68-1.58 (m, 2H) .HRMS (ESI):m/z,
calcd for C27H36N6O2P[M+H+]:507.2637,found 507.2646.
Embodiment 2:
With intermediate 11 (50mg, 0.19mmol) and intermediate 21 (71mg, 0.24mmol) for raw material, using embodiment 1
Identical method synthesizes, and prepares embodiment 2:Off-white powder 84mg, yield is 84%.
Structure verification data are as follows:1H NMR(DMSO-d6)δ(ppm):11.51(s,1H),8.66(m,1H),8.24(s,
1H), 8.02 (d, J=3.2Hz, 1H), 7.54 (dd, J1=13.6Hz, J2=7.6Hz, 1H), 7.32 (t, J=7.6Hz, 1H),
7.21 (d, J=8.4Hz, 1H), 7.08 (t, J=7.2Hz, 1H), 6.44 (d, J=8.8Hz, 1H), 4.49 (t, J=8.4Hz,
2H), 3.41-3.39 (m, 2H), 3.16 (t, J=8.0Hz, 2H), 3.01 (m, 1H), 2.64 (t, J=12.0Hz, 2H), 2.53
(s, 6H), 2.01 (d, J=10.0Hz, 2H), 1.80 (s, 3H), 1.77 (s, 3H), 1.80-1.65 (m, 2H) .HRMS (ESI):
m/z,calcd for C27H35N6O2PF[M+H+]:525.2543,found 525.2557.
Embodiment 3:
With intermediate 11 (40mg, 0.15mmol) and intermediate 22 (54mg, 0.19mmol) for raw material, using embodiment 1
Identical method synthesizes, and prepares embodiment 3:Off-white powder 35mg, yield is 45%.
Structure verification data are as follows:1H NMR(DMSO-d6)δ(ppm):10.95(s,1H),8.51-8.50(m,1H),
8.11 (s, 1H), 7.95 (d, J=5.6Hz, 1H), 7.52 (d, J1=12.8Hz, J2=6.4Hz, 1H), 7.31 (t, J=
7.6Hz, 1H), 7.25 (d, J=8.4Hz, 1H), 7.04 (d, J=7.6Hz, 1H), 6.43 (d, J=8.8Hz, 1H), 5.96 (d,
J=5.6Hz, 1H), 4.49 (t, J=8.4Hz, 2H), 3.39 (m, 2H), 3.17-3.13 (m, 3H), 2.63 (t, J=12.0Hz,
2H),2.43(s,6H),1.97-1.94(m,2H),1.78(s,3H),1.75(s,3H),1.62-1.59(m,2H).HRMS
(ESI):m/z,calcd for C27H36N6O2P[M+H+]:507.2637,found 507.2634.
Embodiment 4 and embodiment 5:
With intermediate 11 (65mg, 0.25mmol) and intermediate 23,24 (108mg, 0.31mmol) for raw material, using implementation
The identical method of example 1 synthesizes, and prepares embodiment compound 4 and 5:Off-white powder 60mg.
Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):10.81(s,1H),10.36(s,0.5H),8.49-
8.48 (m, 1H), 8.35-8.32 (m, 2H), 7.90 (d, J=7.6Hz, 1H), 7.79 (d, J=7.6Hz, 0.5H), 7.46-
7.34 (m, 1.5H), 7.27-7.17 (m, 1.5H), 7.06-7.05 (m, 1.5H), 6.95 (s, 1.5H), 6.49 (d, J=
8.4Hz,1H),6.37(brs,0.5H),4.65-4.61(m,3H),3.49-3.43(m,3H),3.21-3.17(m,3H),3.00
(m, 1.5H), 2.77-2.72 (m, 12H), 2.25 (d, J=10.8Hz, 3H), 1.91-1.89 (m, 3H), 1.84 (s, 4.5H),
1.81(s,4.5H).HRMS(ESI):m/z,calcd for C28H35N6O2PF3[M+H+]:575.2511,found
575.2527.
Embodiment 6:
With intermediate 11 (40mg, 0.15mmol) and 25 (54mg, 0.19mmol) for raw material, using the identical of embodiment 1
Method synthesizes, and prepares embodiment compound 6:Off-white powder 13mg, yield is 17%.
Structure verification data are as follows:1H NMR(DMSO-d6)δ(ppm):11.17(s,1H),9.14(brs,1H),8.41
(brs,1H),8.23(s,1H),7.53(m,1H),7.24(m,1H),7.09-7.07(m,2H),6.46(m,1H),4.50(t,J
=8.4Hz, 2H), 3.33 (m, 2H), 3.17 (m, 3H), 3.05 (m, 1H), 2.65 (t, J=11.2Hz, 2H), 2.50 (s, 6H),
1.97(m,2H),1.78(s,3H),1.75(s,3H),1.64-1.61(m,2H).HRMS(ESI):m/z,calcd for
C26H35N7O2P[M+H+]:508.2590,found 508.2596.
Embodiment 7:
With intermediate 11 (50mg, 0.19mmol) and 26 (75mg, 0.24mmol) for raw material, using the identical of embodiment 1
Method synthesizes, and prepares embodiment compound 7:Off-white powder 74mg, yield is 72%.
Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):10.84(s,1H),8.63(dd,J1=8.4Hz, J2
=4.4Hz, 1H), 8.08 (s, 1H), 7.80 (d, J=8.4Hz, 1H), 7.46 (t, J=8.0Hz, 1H), 7.29-7.24 (m,
1H), 7.11 (d, J=6.8Hz, 1H), 6.81 (s, 1H), 6.43 (d, J=8.4Hz, 1H), 4.60 (t, J=8.8Hz, 2H),
3.38 (d, J=12.0Hz, 2H), 3.21 (t, J=8.4Hz, 2H), 2.66 (t, J=12.0Hz, 2H), 2.33 (s, 6H),
2.30-2.23 (m, 1H), 1.93 (d, J=11.6Hz, 2H), 1.85 (s, 3H), 1.81 (s, 3H), 1.69-1.60 (m, 2H)
.HRMS(ESI):m/z,calcd for C27H35N6O2PCl[M+H+]:541.2248,found 541.2257.
Embodiment 8:
With intermediate 14 (40mg, 0.17mmol) and 26 (67mg, 0.21mmol) for raw material, using the identical of embodiment 1
Method synthesizes, and prepares embodiment 8:Off-white powder 40mg, yield is 46%.
Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):10.86(s,1H),8.62(dd,J1=8.0Hz, J2
=4.4Hz, 1H), 8.08 (s, 1H), 7.84 (d, J=8.4Hz, 1H), 7.46 (t, J=8.0Hz, 1H), 7.30-7.27 (m,
1H), 7.11 (d, J=6.4Hz, 1H), 6.83 (s, 1H), 6.46 (d, J=8.8Hz, 1H), 4.61 (t, J=8.8Hz, 2H),
3.20 (d, J=8.4Hz, 2H), 3.12-3.07 (m, 4H), 2.45 (s, 3H), 1.85 (s, 3H), 1.82 (s, 3H), 1.41 (t, J
=7.2Hz, 2H) .HRMS (ESI):m/z,calcd for C25H31N6O2PCl[M+H+]:513.1935,found
513.1924.
Embodiment 9:
With intermediate 13 (40mg, 0.12mmol) and 26 (47mg, 0.15mmol) for raw material, using the identical of embodiment 1
Method synthesizes, and prepares embodiment 9:White solid 14mg, yield is 22%.
Structure verification data are as follows:1H NMR(DMSO-d6)δ(ppm):11.21(s,1H),8.53(brs,1H),8.47
(s,1H),8.07(s,1H),7.53(dd,J1=14.0Hz, J2=8.4Hz, 1H), 7.29 (m, 1H), 7.17 (d, J=8.8Hz,
1H), 7.10-7.08 (m, 1H), 6.45 (d, J=8.4Hz, 1H), 5.76 (s, 1H), 4.49 (t, J=8.0Hz, 2H), 3.30
(m,4H),3.19-3.12(m,6H),1.78(s,3H),1.75(s,3H).HRMS(ESI):m/z,calcd for
C24H29N6O2PCl[M+H+]:499.1778,found 499.1779.
Embodiment 10:
With intermediate 12 (35mg, 0.14mmol) and 26 (55mg, 0.18mmol) for raw material, using the identical of embodiment 1
Method synthesizes, and prepares embodiment 10:White solid 60mg, yield is 81%.
Structure verification data are as follows:1H NMR(DMSO-d6)δ(ppm):11.19(s,1H),8.56(brs,1H),8.31
(s,1H),8.03(s,1H),7.51(dd,J1=14.0Hz, J2=7.2Hz, 1H), 7.28 (m, 1H), 7.77 (t, J=6.8Hz,
1H), 6.98 (d, J=8.4Hz, 1H), 6.09 (d, J=8.4Hz, 1H), 4.46-4.35 (m, 2H), 3.52-3.24 (m, 6H),
2.90(m,1H),2.29(s,6H),2.13-2.09(m,1H),1.78(m,1H),1.75(s,3H),1.74(s,3H).HRMS
(ESI):m/z,calcd for C26H33N6O2PCl[M+H+]:527.2091,found 527.2104.
Embodiment 11:
With intermediate 15 (40mg, 0.13mmol) and 26 (50mg, 0.16mmol) for raw material, using the identical of embodiment 1
Method synthesizes, and prepares embodiment 11:Off-white powder 35mg, yield is 46%.
Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):10.85(s,1H),8.63(dd,J1=8.0Hz, J2
=4.0Hz, 1H), 8.08 (s, 1H), 7.81 (d, J=8.8Hz, 1H), 7.46 (t, J=7.2Hz, 1H), 7.30-7.25 (m,
1H), 7.11 (d, J=7.6Hz, 1H), 6.81 (s, 1H), 6.42 (d, J=8.8Hz, 1H), 4.61 (t, J=8.4Hz, 2H),
3.40 (d, J=13.6Hz, 2H), 3.19 (t, J=8.0Hz, 2H), 2.92-2.51 (m, 13H), 2.01 (m, 2H), 1.85 (s,
3H),1.81(s,3H),1.79-1.75(m,2H).HRMS(ESI):m/z,calcd for C30H40N7O2PCl[M+H+]:
596.2670,found 596.2673.
Embodiment 12:
With intermediate 16 (30mg, 0.13mmol) and 26 (50mg, 0.16mmol) for raw material, using the identical of embodiment 1
Method synthesizes, and prepares embodiment 12:Off-white powder 25mg, yield is 38%.
Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):10.85(s,1H),8.61(m,1H),8.10(s,
1H),7.97(m,1H),7.48(m,1H),7.26(m,1H),7.13(m,1H),7.00(s,1H),6.74(m,1H),5.79(s,
1H),4.59(m,2H),3.32-3.11(m,4H),2.66-2.34(m,7H),1.85(s,3H),1.82(s,3H).HRMS
(ESI):m/z,calcd for C26H30N5O2PCl[M+H+]:510.1826,found 510.1830.
Embodiment 13:
With intermediate 17 (40mg, 0.17mmol) and 26 (67mg, 0.21mmol) for raw material, using the identical of embodiment 1
Method synthesizes, and prepares embodiment 13:Off-white powder 28mg, yield is 38%.
Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):10.84(s,1H),8.61-8.60(m,1H),8.09
(s, 1H), 7.94 (d, J=8.0Hz, 1H), 7.46 (t, J=8.0Hz, 1H), 7.30-7.26 (m, 1H), 7.14 (t, J=
6.4Hz, 1H), 6.93 (s, 1H), 6.72 (t, J=7.2Hz, 1H), 4.62 (t, J=8.4Hz, 2H), 3.24 (t, J=8.4Hz,
2H), 3.02 (d, J=10.0Hz, 2H), 2.44-2.36 (m, 4H), 2.08-2.05 (m, 2H), 1.89-1.82 (m, 10H)
.HRMS(ESI):m/z,calcd for C26H32N5O2PCl[M+H+]:512.1982,found 512.1970.
Embodiment 14:
Intermediate 18 (30mg, 0.09mmol) is dissolved in toluene (4mL), Pd is sequentially added2(dba)3(8mg,
0.009mmol), DavePhos (8mg, 0.018mmol) and K3PO4(40mg, 0.018mmol, 0.4mL H2O), stir
Afterwards, intermediate 26 (34mg, 0.11mmol) is added, under argon gas protection, 90 DEG C of reaction 1h, raw material disappears.Room temperature is cooled to, is evaporated off
Solvent, EA (30mL) dissolution residual substance, saturated common salt washing (20mL × 3) is washed (20mL × 2), column chromatography (D/M=10:
1) embodiment 14, is obtained:White powdery solids 36mg, yield is 64%.
Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):10.86(s,1H),8.61(dd,J1=8.4Hz, J2
=4.4Hz, 1H), 8.10 (s, 1H), 7.94 (d, J=8.0Hz, 1H), 7.48 (t, J=8.0Hz, 1H), 7.31-7.26 (m,
1H), 7.16-7.12 (m, 1H), 6.93 (s, 1H), 6.65 (d, J=8.8Hz, 1H), 4.63 (t, J=8.4Hz, 2H), 4.27
(m, 2H), 3.25 (t, J=8.4Hz, 2H), 2.79 (t, J=12.4Hz, 2H), 2.62-2.56 (m, 1H), 1.85 (s, 3H),
1.82(s,3H),1.79-1.63(m,4H),1.50(s,9H).
Embodiment 15:
Intermediate 19 (40mg, 0.13mmol) is dissolved in toluene (6mL), Pd is sequentially added2(dba)3(11mg,
0.013mmol), DavePhos (10mg, 0.025mmol) and K3PO4(53mg, 0.25mmol, 1mL H2O), after stirring,
Compound 26 (58mg, 0.15mmol) is added, under argon gas protection, 90 DEG C of reaction 4h, raw material disappears.Room temperature is cooled to, is evaporated off molten
Agent, EA (30mL) dissolution residual substance, saturated common salt washing (20mL × 3) is washed (20mL × 2), column chromatography (D/M=20:1),
Obtain embodiment 16:White powdery solids 70mg, yield is 81%.
Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):10.83(s,1H),8.62(dd,J1=8.0Hz, J2
=4.4Hz, 1H), 8.08 (s, 1H), 7.80 (d, J=8.4Hz, 1H), 7.46 (t, J=7.2Hz, 1H), 7.26 (m, 1H),
7.13-7.11 (m, 1H), 6.82 (s, 1H), 6.42 (d, J=8.8Hz, 1H), 4.60 (t, J=8.0Hz, 2H), 3.53-3.38
(m, 6H), 3.19 (t, J=8.4Hz, 2H), 2.70-2.64 (m, 7H), 1.97 (brs, 2H), 1.85 (s, 3H), 1.81 (s,
3H),1.64(m,2H),1.47(s,9H).
Embodiment 16:
Embodiment 14 (28mg, 0.05mmol) is dissolved in DCM (4mL), TFA (0.5mL), room temperature reaction 3h is added, it is former
Material disappears.Room temperature is cooled to, solvent is evaporated off, obtain embodiment 16:White powdery solids 136mg, yield is 57%.
Structure verification data are as follows:1H NMR(CDCl3)δ(ppm):10.02(s,1H),10.73(brs,1H),9.82(s,
1H), 9.37 (s, 1H), 8.47 (s, 1H), 7.41 (d, J=7.6Hz, 1H), 7.26-7.21 (m, 3H), 6.74 (d, J=
8.0Hz, 1H), 4.61 (t, J=8.0Hz, 2H), 3.59 (d, J=9.2Hz, 2H), 3.24 (t, J=8.0Hz, 2H), 3.07 (m,
2H), 2.79 (m, 1H), 2.19-2.15 (m, 2H), 2.01 (d, J=12.8Hz, 2H) .1.87 (s, 3H), 1.84 (s, 3H)
.HRMS(ESI):m/z,calcd for C25H30N5O2PCl[M+H+]:498.1826,found 498.1826.
Embodiment 17:
Embodiment 15 (40mg, 0.06mmol) is dissolved in DCM (4mL), TFA (0.5mL), room temperature reaction 3h is added, it is former
Material disappears.Room temperature is cooled to, solvent is evaporated off, obtain embodiment 17:White powdery solids 40mg, yield is 78%.
Structure verification data are as follows:1H NMR(DMSO-d6)δ(ppm):11.38(s,1H),9.16(brs,2H),8.73
(s,1H),8.52(s,1H),8.10(s,1H),7.56-7.52(m,1H),7.30(s,1H),7.16-7.11(m,2H),6.46
(d, J=8.4Hz, 2H), 4.50 (t, J=8.0Hz, 2H), 3.75 (m, 4H), 3.49-3.40 (m, 6H), 3.19-3.08 (m,
3H), (m, the 5H) .HRMS of 2.70 (t, J=11.6Hz, 2H), 2.12 (d, J=10.0Hz, 2H), 1.79 (s, 3H), 1.76
(ESI):m/z,calcd for C29H38N7O2PCl[M+H+]:582.2513,found 582.2516.
Test case 1, the compounds of this invention is to ALKwt/ALKL1196MThe measure of kinase activity
Embodiment compound 12000g is centrifuged 5min, adds DMSO to be configured to 10-2M liquid storages, be vortexed uniform rear ultrasound 10min
Stand-by, -40 DEG C preserve (compound for having special storage requirement is changed according to concrete condition).During test by compound with DMSO from
Liquid storage is diluted to 100 times (DMSO concentration is 1% in system) of institute's test concentrations.
Method of testing:
1st, enzyme reaction substrate Poly (Glu, Tyr) 4:1 with PBS (10mM sodium phosphate buffers, 150mM without potassium ion
NaCl, pH7.2-7.4) 20 μ g/mL are diluted to, 125 μ L/ holes coated elisa plates are put 37 DEG C and are reacted 12-16 hours.In discarding hole
Liquid.Board-washing, with T-PBS (PBS without potassium ion containing 0.1%Tween-20,200 μ L/ holes) board-washing three times, every time 5 minutes.
Dried in 37 DEG C of baking ovens ELISA Plate 1-2 hours;
2nd, added with reaction buffer (50mM HEPES pH 7.4,50mM MgCl per hole2,0.5mM MnCl2,0.2mM
Na3VO4, 1mM DTT) dilution the μ L of ATP solution 49, add 1 μ L compounds to be tested per in hole, 50 μ L are added to react slow
The ALK of fliud flushing dilutionwt/ALKL1196MKinase domain recombinant protein starts reaction, and experiment every time need to be set without ATP control wells holes.Put 37
DEG C shaking table (100rpm) reacts 1 hour.Discard liquid in hole, T-PBS board-washings three times;
3rd, antibody PY99 dilutions (T-PBS 1 of the antibody containing BSA 5mg/mL is added:500 dilutions), 100 μ L/ holes, 37
DEG C shaking table reacts 0.5 hour.Discard liquid in hole, T-PBS board-washings three times;
4th, the sheep anti mouse secondary antibody dilution (T-PBS of the antibody containing BSA 5mg/ml of horseradish peroxidase-labeled is added
1:2000 dilutions), 100 μ L/ holes, 37 DEG C of shaking tables react 0.5 hour.Discard liquid in hole, T-PBS board-washings three times;
5th, the μ L/ holes of OPD nitrite ions 100 of 2mg/ml are added【With containing 0.03%H2O20.1M citric acid-sodium citrates
Buffer solution (pH=5.4) dilutes】, 25 DEG C of lucifuges react 1-10 minutes;
6th, 2M H are added2SO450 μ L/ holes stopped reactions, are declined orifice plate ELIASA VERSAmax readings, ripple with wavelengthtunable
A length of 490nm;
7th, interpretation of result, IC50Value is used the random bundled software of ELIASA to be returned with four parametric methods and tried to achieve.
0<IC50<100nM, is designated as " +++ ";100nM<IC50<500nM, is designated as " ++ ";IC50>500nM, is designated as "+".
Experimental result is as shown in table 1.
The computing formula of inhibiting rate is as follows:
Table 1, embodiment 1-18 compounds are to ALKwt/ALKL1196MThe inhibitory activity of kinases
Test case 2:Inhibitory activity of the compound to other kinases
ALK is tested using the kinases screening technique similar with test case 1L1152, ALKG1202, ALKF1245, ALKC1156,
ALKG1269, ALKS1206, EGFRwt,EGFR TT90M,EGFR T790M/L858R, the inhibitory activity of the kinases such as ROS.As a result display portion
The embodiment compound such as grade of embodiment 7,8,9,12,13,16 is to ALKL1152, ALKG1202, ALKF1245, ALKC1156, ALKG1269,
ALKS1206, the inhibitory activity IC50 of ROS kinases is respectively less than 100nM, it is shown that preferable inhibitory activity;Meanwhile, above-claimed cpd
To EGFRwt,EGFR TT90M,EGFR T790M/L858RInhibitory activity IC50 Deng kinases is less than 500nM, equally also show higher
Activity.
Test case 3:Compound on intracellular proliferation inhibition activity
By the work of the single Solution Cell Proliferation experimental evaluation embodiment compound on intracellular Proliferation Abilities of Cell Titer 96
Property.After inoculation 24 hours, using embodiment compound treatment cell, grow 72 hours.It is thin in zero moment (process time) correction
Born of the same parents are counted, and growth of the Microsoft Excel draftings relative to control group (DMSO) is carried out using XLfit version 4.2.2
Percentage data, determines the concentration (GI50 values) for suppressing 50% growth.Result shows, embodiment compound 7,8,9,12,13,16
Deng to NCI-H3122 and EML4-ALKG1202There is stronger proliferation inhibition activity Deng cell line, IC50 is less than 100nM;Meanwhile,
To H1975, the cell line such as A431, SK-N-SH also has preferable inhibitory activity to above-claimed cpd, and IC50 is less than 500nM.
Claims (10)
1. compound shown in formula I, its pharmaceutically acceptable salt, enantiomter, diastereoisomer, dynamic isomer, molten
Agent compound, polymorph or its prodrug;Or
Compound shown in formula I ', its pharmaceutically acceptable salt, enantiomter, diastereoisomer, dynamic isomer, solvent
Compound, polymorph or its prodrug;
In formula I or formula I ':
R1、R2、R3、R4Appointing in hydrogen, halogen, cyano group, hydroxyl, amino and substituted or unsubstituted C1-C6 alkyl
One kind, and R1、R2、R3、R4In any two group can be formed 3-10 unit ring system;
M1、M2、M3Independently selected from CRa or N, and M1、M2And M3In at least one be N;Ra be hydrogen, halogen, cyano group, substitution or
One kind in unsubstituted C1-C6 alkyl and substituted or unsubstituted C3-C8 cycloalkyl;
W is selected from any one of following radicals:Substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyls,
Unsubstituted or halo 4~8 yuan of alkynyl group, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 4-8 units are miscellaneous
Ring group, the aromatic radical or heteroaryl, substituted carbonyl, substituted sulphonyl, substituted or unsubstituted amino of 5-10 units, wherein, it is described
Heterocyclic radical is comprising 1-3 selected from the hetero atom in N, O, S, P and B;
The substitution base that described one or more groups being substituted by group are selected from the following group is replaced:Halogen, hydroxyl, amino,
Cyano group, unsubstituted or halo C1-C8 alkyl, unsubstituted or halo C3-C8 cycloalkyl, unsubstituted or halo C1-C8 alkane
Epoxide, unsubstituted or halo C2-C6 alkenyls, unsubstituted or halo C2-C6 alkynyls, unsubstituted or halo C2-C6 acyl groups,
Unsubstituted or halo 5~8 yuan of aryl, unsubstituted or halo 5~8 unit's heteroaryls, unsubstituted or halo 4~8 yuan of saturations
Heterocycle, unsubstituted or halo 4~8 yuan of carbocyclic rings;Wherein, the heteroaryl includes the 1-3 hetero atom being selected from N, O and S, institute
State heterocycle and include the 1-3 hetero atom selected from N, O and S;
In formula I ', L is selected from any one of following radicals:- CR ' R "-,-O- ,-NR '-and-CR '=, wherein R ' and R " each solely
It is on the spot hydrogen, fluorine, deuterium, C1-C6 alkyl or Heterocyclylalkyl, or adjacent R ' and R " form cyclic group.
2. compound shown in formula according to claim 1 I or its enantiomter, diastereoisomer, dynamic isomer,
Solvate, polymorph, prodrug or pharmaceutically acceptable salt;Or
It is compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorph, preceding
Medicine or pharmaceutically acceptable salt, it is characterised in that:
Compound shown in formula I or compound shown in formula I ' meet it is following 1) and/or 2):
1) in formula I or formula I ', M1、M2Independently selected from CH or N, and M1And M2In at least one be N;M3Selected from C-F, C-CF3、
Any one in C-Cl, CH and N;
2) in formula I or formula I ', W is selected from any one in following radicals:Substituted or unsubstituted C1-C6 alkyl or cycloalkyls, take
Generation or unsubstituted 4-6 circle heterocycles, substituted or unsubstituted 4-10 unit's cycloalkyl and substituted or unsubstituted 4-10 circle heterocycles alkane
Volution or bridged ring that base is formed;
It is described substitution refer to substitution base independently selected from:Halogen, hydroxyl, cyano group, amino, alkyl, alkyl monosubstituted amino, dialkyl amino
Base, cycloalkyl, heterocyclic radical, alkoxy, hydroxy alkyl, alkoxyalkyl, hydroxy alkoxy alkyl, aminoalkyl, dialkyl amino
Base alkyl, alkoxycarbonylamino, cycloalkyl-alkyl, cycloheteroalkylalkyl, aralkyl, alkyl-cycloalkyl, naphthene base carbonyl,
Alkoxy carbonyl, alkoxy carbonyl heterocyclic radical, (alkoxy carbonyl group) (alkyl) amino, (alkoxyalkyl) (alkyl) amino.
3. compound shown in formula according to claim 1 and 2 I or its enantiomter, diastereoisomer, tautomerism
Body, solvate, polymorph, prodrug or pharmaceutically acceptable salt;Or
It is compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorph, preceding
Medicine or pharmaceutically acceptable salt, it is characterised in that:
Compound shown in formula I is any one in compound shown in the compound to-w of formula I shown in the-a of following formula I:
Concretely in the-a of the following formula I ' to-c of formula I ' any one of compound shown in formula I ':
4. prepare compound shown in the formula I any one of claim 1-3 or its enantiomter, diastereoisomer,
Dynamic isomer, solvate, polymorph, prodrug or pharmaceutically acceptable salt;Or
It is compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorph, preceding
The method of medicine or pharmaceutically acceptable salt, comprises the following steps:
(1) by compound shown in formula IV and compound shown in formula V, in the condition that transition-metal catalyst and/or acid/base are present
Under be coupled, obtain compound shown in formula III;
In formula IV, X and LG is each independently leaving group, and selected from any in halogen, sulphonic acid ester, boric acid and borate
Kind;
In formula III, the definition of X is with formula IV;M1、M2And M3Definition with formula I;
(2) compound shown in formula III and compound shown in formula II or compound shown in formula II ' in transition-metal catalyst and/or
Acid/base is coupled under conditions of existing, and obtains compound shown in Formulas I;
In formula II, R1、R2、R3、R4Definition with W is with formula I;In formula II ', R1、R2、R3、R4, L and W definition with formula I '.
5. method according to claim 4, it is characterised in that:In step (1) or step (2),
The coupling reaction is carried out in a solvent, and the solvent is selected from water, methyl alcohol, ethanol, isopropanol, ethylene glycol, N- methyl
Pyrrolidones, dimethyl sulfoxide (DMSO), tetrahydrofuran, toluene, dichloromethane, 1,2- dichloroethanes, acetonitrile, N, N- dimethyl formyls
At least one in amine, DMAC N,N' dimethyl acetamide and dioxane;
The transition-metal catalyst be selected from three (dibenzalacetone) two palladium, tetrakis triphenylphosphine palladium, palladium, palladium bichloride,
Dichloro two (triphenylphosphine) palladium, trifluoracetic acid palladium, triphenylphosphine palladium acetate, [double (diphenylphosphino) ferrocene of 1,1'-] dichloro
Change at least one in palladium, double (three adjacent benzyl phosphines) palladium chlorides and 1,2- bis- (diphenylphosphino) ethane palladium chloride;Institute
State catalyst ligand and be selected from tri-butyl phosphine, tetrafluoro boric acid tri-butyl phosphine, tri-n-butyl phosphine, triphenylphosphine, three pairs of benzyls
At least one in the adjacent benzyl phosphine of phosphine, tricyclohexyl phosphine and three;
The alkali is inorganic base or organic base;The inorganic base is selected from sodium hydride, potassium hydroxide, sodium acetate, potassium acetate, the tert-butyl alcohol
In potassium, sodium tert-butoxide, potassium fluoride, cesium fluoride, potassium phosphate, potassium carbonate, saleratus, sodium carbonate and sodium acid carbonate at least one
Kind;The organic base is selected from pyridine, triethylamine, DIPEA, the carbon -7- of 1,8- diazabicylos [5.4.0] 11
At least one in alkene, the silicon substrate lithium of hexamethyl two, the silicon substrate sodium of hexamethyl two and lutidines;
The acid is selected from least one in hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, formic acid and acetic acid.
6. compound shown in the formula I any one of claim 1-3, its pharmaceutically acceptable salt, enantiomter, non-
Enantiomter, dynamic isomer, solvate, polymorph or its prodrug;Or
Compound shown in formula I ', its pharmaceutically acceptable salt, enantiomter, diastereoisomer, dynamic isomer, solvent
Compound, polymorph or its prodrug;
Preparing the application having in the inhibitor of the function of suppressing EGFR mutant kinase activities and/or ALK kinase activity.
7. a kind of kinase inhibitor, compound or its enantiomerism shown in the formula I that it includes any one of claim 1-3
Body, diastereoisomer, dynamic isomer, solvate, polymorph, prodrug or pharmaceutically acceptable salt;Or
It is compound shown in formula I ' or its enantiomter, diastereoisomer, dynamic isomer, solvate, polymorph, preceding
Medicine or pharmaceutically acceptable salt.
8. compound shown in the formula I any one of claim 1-3, its pharmaceutically acceptable salt, enantiomter, non-
Enantiomter, dynamic isomer, solvate, polymorph or its prodrug;Or
Compound shown in formula I ', its pharmaceutically acceptable salt, enantiomter, diastereoisomer, dynamic isomer, solvent
Compound, polymorph or its prodrug;
Application in prevention and/or treatment tumour product is prepared.
9. application according to claim 8, it is characterised in that:The tumour is non-small cell lung cancer, ED-SCLC, lung
Gland cancer, lung squamous cancer, cancer of pancreas, breast cancer, prostate cancer, liver cancer, cutaneum carcinoma, cell carcinoma, gastrointestinal stromal tumor, white blood
Any one in disease, lymph cancer and nasopharyngeal carcinoma.
10. a kind of pharmaceutical composition, it is characterised in that:It includes:
1) compound, its pharmaceutically acceptable salt, mapping shown in the formula I any one of the claim 1-4 of effective dose
Isomers, diastereoisomer, dynamic isomer, solvate, polymorph or its prodrug;With
2) pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510788838 | 2015-11-17 | ||
CN2015107888386 | 2015-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106699810A true CN106699810A (en) | 2017-05-24 |
Family
ID=58717344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611021938.7A Pending CN106699810A (en) | 2015-11-17 | 2016-11-16 | Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN106699810A (en) |
WO (1) | WO2017084640A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019015655A1 (en) * | 2017-07-19 | 2019-01-24 | 正大天晴药业集团股份有限公司 | Aryl-phosphorus-oxygen compound as egfr kinase inhibitor |
CN109369721A (en) * | 2017-12-21 | 2019-02-22 | 深圳市塔吉瑞生物医药有限公司 | For inhibiting the aryl phosphorous oxides of kinase activity |
WO2020147838A1 (en) * | 2019-01-18 | 2020-07-23 | 正大天晴药业集团股份有限公司 | Salt of egfr inhibitor, crystal form, and preparation method therefor |
WO2020216371A1 (en) * | 2019-04-26 | 2020-10-29 | 江苏先声药业有限公司 | Egfr inhibitor and application thereof |
CN112824420A (en) * | 2019-11-21 | 2021-05-21 | 浙江同源康医药股份有限公司 | Compounds useful as EGFR kinase inhibitors and uses thereof |
CN113527281A (en) * | 2020-04-20 | 2021-10-22 | 昆山彭济凯丰生物科技有限公司 | Heterocyclic compounds, their preparation and use |
WO2022199589A1 (en) * | 2021-03-23 | 2022-09-29 | 南京明德新药研发有限公司 | Pyrimidine derivatives |
WO2022253081A1 (en) * | 2021-06-03 | 2022-12-08 | 希格生科(深圳)有限公司 | Phosphine oxide derivative, preparation method therefor and application thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220259235A1 (en) * | 2019-07-26 | 2022-08-18 | Betta Pharmaceuticals Co., Ltd | EGFR Inhibitor, Composition, and Preparation Method Therefor |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009143389A1 (en) * | 2008-05-21 | 2009-11-26 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
CN103153064A (en) * | 2010-10-14 | 2013-06-12 | 阿里亚德医药股份有限公司 | Methods for inhibiting cell proliferation in EGFR-driven cancers |
WO2014071832A1 (en) * | 2012-11-06 | 2014-05-15 | Shanghai Fochon Pharmaceutical Co Ltd | Alk kinase inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001237041B9 (en) * | 2000-02-17 | 2005-07-28 | Amgen Inc. | Kinase inhibitors |
US8592432B2 (en) * | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
-
2016
- 2016-11-16 CN CN201611021938.7A patent/CN106699810A/en active Pending
-
2017
- 2017-01-06 WO PCT/CN2017/070372 patent/WO2017084640A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009143389A1 (en) * | 2008-05-21 | 2009-11-26 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
CN102105150A (en) * | 2008-05-21 | 2011-06-22 | 阿里亚德医药股份有限公司 | Phosphorous derivatives as kinase inhibitors |
CN103153064A (en) * | 2010-10-14 | 2013-06-12 | 阿里亚德医药股份有限公司 | Methods for inhibiting cell proliferation in EGFR-driven cancers |
WO2014071832A1 (en) * | 2012-11-06 | 2014-05-15 | Shanghai Fochon Pharmaceutical Co Ltd | Alk kinase inhibitors |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113354685A (en) * | 2017-07-19 | 2021-09-07 | 正大天晴药业集团股份有限公司 | Aryl phosphorus oxide compounds as EGFR kinase inhibitors |
KR20200032146A (en) * | 2017-07-19 | 2020-03-25 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Aryl-phosphorus-oxygen compounds as EGFR kinase inhibitors |
CN110944989A (en) * | 2017-07-19 | 2020-03-31 | 正大天晴药业集团股份有限公司 | Aryl phosphorus oxide compounds as EGFR kinase inhibitors |
WO2019015655A1 (en) * | 2017-07-19 | 2019-01-24 | 正大天晴药业集团股份有限公司 | Aryl-phosphorus-oxygen compound as egfr kinase inhibitor |
KR102647277B1 (en) | 2017-07-19 | 2024-03-12 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Aryl-phospho-oxygen compounds as EGFR kinase inhibitors |
CN113354685B (en) * | 2017-07-19 | 2022-12-20 | 正大天晴药业集团股份有限公司 | Aryl phosphorus oxide compounds as EGFR kinase inhibitors |
CN110944989B (en) * | 2017-07-19 | 2021-06-25 | 正大天晴药业集团股份有限公司 | Aryl phosphorus oxide compounds as EGFR kinase inhibitors |
US11390625B2 (en) | 2017-07-19 | 2022-07-19 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor |
CN109369721A (en) * | 2017-12-21 | 2019-02-22 | 深圳市塔吉瑞生物医药有限公司 | For inhibiting the aryl phosphorous oxides of kinase activity |
WO2019120094A1 (en) * | 2017-12-21 | 2019-06-27 | 深圳市塔吉瑞生物医药有限公司 | Arylphosphine oxides for inhibiting kinase activity |
CN109369721B (en) * | 2017-12-21 | 2024-05-14 | 深圳市塔吉瑞生物医药有限公司 | Aryl phosphorus oxides for inhibiting kinase activity |
WO2020147838A1 (en) * | 2019-01-18 | 2020-07-23 | 正大天晴药业集团股份有限公司 | Salt of egfr inhibitor, crystal form, and preparation method therefor |
CN113260613A (en) * | 2019-01-18 | 2021-08-13 | 正大天晴药业集团股份有限公司 | Salts and crystal forms of EGFR inhibitor and preparation method thereof |
CN113260613B (en) * | 2019-01-18 | 2022-12-30 | 正大天晴药业集团股份有限公司 | Salts and crystal forms of EGFR inhibitor and preparation method thereof |
CN113166103A (en) * | 2019-04-26 | 2021-07-23 | 江苏先声药业有限公司 | EGFR inhibitor and application thereof |
WO2020216371A1 (en) * | 2019-04-26 | 2020-10-29 | 江苏先声药业有限公司 | Egfr inhibitor and application thereof |
CN112824420B (en) * | 2019-11-21 | 2022-04-26 | 浙江同源康医药股份有限公司 | Compounds useful as EGFR kinase inhibitors and uses thereof |
WO2021098883A1 (en) * | 2019-11-21 | 2021-05-27 | 浙江同源康医药股份有限公司 | Compound used as egfr kinase inhibitor and use thereof |
CN112824420A (en) * | 2019-11-21 | 2021-05-21 | 浙江同源康医药股份有限公司 | Compounds useful as EGFR kinase inhibitors and uses thereof |
CN113527281A (en) * | 2020-04-20 | 2021-10-22 | 昆山彭济凯丰生物科技有限公司 | Heterocyclic compounds, their preparation and use |
CN113527281B (en) * | 2020-04-20 | 2023-12-22 | 昆山彭济凯丰生物科技有限公司 | Heterocyclic compounds, process for their preparation and their use |
WO2022199589A1 (en) * | 2021-03-23 | 2022-09-29 | 南京明德新药研发有限公司 | Pyrimidine derivatives |
WO2022253081A1 (en) * | 2021-06-03 | 2022-12-08 | 希格生科(深圳)有限公司 | Phosphine oxide derivative, preparation method therefor and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2017084640A1 (en) | 2017-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106699810A (en) | Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity | |
ES2904544T3 (en) | Indazole compounds as FGFR kinase inhibitors, preparation and use thereof | |
CA2853367C (en) | New naphthyridine derivative compounds | |
TWI715901B (en) | Bicyclic heterocycles as fgfr inhibitors | |
CN104507943B (en) | Substituted tricyclic compound as FGFR inhibitor | |
BR112021008714A2 (en) | spiroaromatic ring compounds of formula I, method of preparation, pharmaceutical composition and use thereof | |
TWI324159B (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
TWI344466B (en) | Novel compounds that are erk inhibitors | |
KR101961500B1 (en) | Serine/threonine kinase inhibitors | |
CN105263934B (en) | It is used as the ketone derivatives of pyrazoles pyrrolizine 4 and its purposes in treatment disease of BET inhibitor | |
WO2019037678A1 (en) | Pyrazolo[3,4-d]pyrimidin-3-one derivative, pharmaceutical composition and use thereof | |
CN112300160A (en) | Spiro aromatic ring compound, preparation and application thereof | |
WO2016173557A1 (en) | Compound having kinase inhibition activity, and preparation method and uses | |
JPWO2021132422A1 (en) | Pyridadinyl thiaazole carboxamide compound | |
WO2021143701A1 (en) | Pyrimidine-4(3h)-ketone heterocyclic compound, preparation method therefor and use thereof in medicine and pharmacology | |
EA031267B1 (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
ES2936627T3 (en) | Pyrazine-2(1H)-ketone compound as FGFR inhibitor | |
CN110950876B (en) | Furanolactam compounds, preparation method and application | |
TWI818424B (en) | Nitrogen-containing polycyclic fused ring compound, pharmaceutical composition, preparation method and use thereof | |
WO2022063212A1 (en) | Pyrimidyl derivative, preparation method therefor and use thereof | |
CN105085525B (en) | Isoquinolin sulfonyl derivative as RHO kinase inhibitor | |
US20200347061A1 (en) | Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof | |
WO2021083383A1 (en) | Nitrogen-containing fused cyclic compound as sting regulator, and preparation method therefor and use thereof | |
WO2020078360A1 (en) | Preparation and uses of protein receptor kinase inhibitor | |
CN109761986A (en) | Three simultaneously ring analog derivative inhibitor, preparation method and applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170524 |